

10594024

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

10594024

NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:09:02 ON 14 NOV 2008

$\Rightarrow$

## Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n) :

Switching to the Registry File....

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:09:17 ON 14 NOV 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 NOV 2008 HIGHEST RN 1072687-23-0  
DICTIONARY FILE UPDATES: 13 NOV 2008 HIGHEST RN 1072687-23-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/gen/stndoc/properties.html>

10594024

=>

Uploading C:\Program Files\Stnexp\Queries\10594024.str



chain nodes :  
18 19 20 21 22 23 24 25 27  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  
chain bonds :  
1-19 5-20 8-21 14-27 17-18 18-19 18-24 19-22 20-21 20-23 21-25  
ring bonds :  
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14  
14-15 15-16 16-17  
exact/norm bonds :  
1-2 1-5 1-19 8-21 14-27 17-18 18-19 19-22 20-21 20-23  
exact bonds :  
2-3 3-4 4-5 5-20 18-24 21-25  
normalized bonds :  
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17  
isolated ring systems :  
containing 1 : 6 : 12 :


G1:O,X

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS  
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS

10594024

L1 STRUCTURE UPLOADED

=> d 11  
L1 HAS NO ANSWERS  
L1 STR



G1 O,X

Structure attributes must be viewed using STN Express query preparation.

=> s 11  
SAMPLE SEARCH INITIATED 09:09:36 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 77 TO ITERATE  
  
100.0% PROCESSED 77 ITERATIONS 42 ANSWERS  
SEARCH TIME: 00.00.01  
  
FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 1014 TO 2066  
PROJECTED ANSWERS: 452 TO 1228


L2 42 SEA SSS SAM L1

=> s 11 sss full  
FULL SEARCH INITIATED 09:09:43 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1458 TO ITERATE  
  
100.0% PROCESSED 1458 ITERATIONS 649 ANSWERS  
SEARCH TIME: 00.00.01

L3 649 SEA SSS FUL L1

=>  
Uploading C:\Program Files\Stnexp\Queries\10594024a.str

10594024



chain nodes :

18 19 20 21 22 23 24 25 27 30

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

1-19 5-20 8-21 14-27 17-18 18-19 18-24 19-22 20-21 20-23 21-25

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14  
14-15 15-16 16-17

exact/norm bonds :

1-2 1-5 1-19 8-21 14-27 17-18 18-19 19-22 20-21 20-23

exact bonds :

2-3 3-4 4-5 5-20 18-24 21-25

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17

isolated ring systems :

containing 1 : 6 : 12 :

G1:O,X

G2:A,Cy,Hy

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS  
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS 30:CLASS  
31:Atom

L4

STRUCTURE UPLOADED

10594024

=> d 14  
L4 HAS NO ANSWERS  
L4 STR



G1 O,X  
G2 A,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s 14  
SAMPLE SEARCH INITIATED 09:11:54 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 76 TO ITERATE  
  
100.0% PROCESSED 76 ITERATIONS 42 ANSWERS  
SEARCH TIME: 00.00.01  
  
FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 997 TO 2043  
PROJECTED ANSWERS: 451 TO 1227

L5 42 SEA SSS SAM L4

=> s 14 sss full  
FULL SEARCH INITIATED 09:12:02 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1416 TO ITERATE  
  
100.0% PROCESSED 1416 ITERATIONS 646 ANSWERS  
SEARCH TIME: 00.00.01

L6 646 SEA SSS FUL L4

=> FIL HCPLUS  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
358.10 358.31

10594024

FILE 'HCAPLUS' ENTERED AT 09:12:18 ON 14 NOV 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Nov 2008 VOL 149 ISS 21  
FILE LAST UPDATED: 13 Nov 2008 (20081113/ED)

HCAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 13
L7          17 L3



=> s 16
L8          17 L6

=> s 18 and py<=2004
      25113662 PY<=2004
L9          6 L8 AND PY<=2004

=> d 19 ibib abs hitstr tot

L9  ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:857591 HCAPLUS
DOCUMENT NUMBER: 141:314626
TITLE: Method for the production of
      pyrrolidine-1,2-dicarboxylic
      acid-1-(phenyl(-amide))-2-(phenyl(-amide)) derivatives
      and 1-(phenylcarbamoyl)-pyrrolidine-2-carboxylic acid
      derivatives as intermediate products
INVENTOR(S): Mederski, Werner; Tsaklakidis, Christos; Dorsch,
      Dieter; Cezanne, Bertram; Gleitz, Johannes
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
SOURCE: PCT Int. Appl., 42 pp.
        CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087695	A1	20041014	WO 2004-EP2405	20040309 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10315377	A1	20041014	DE 2003-10315377	20030403 <--
DE 10327428	A1	20050105	DE 2003-10327428	20030618
DE 10329295	A1	20050203	DE 2003-10329295	20030630
DE 10329457	A1	20050120	DE 2003-10329457	20030701
DE 10334174	A1	20050217	DE 2003-10334174	20030726
AU 2004226280	A1	20041014	AU 2004-226280	20040309 <--
CA 2520893	A1	20041014	CA 2004-2520893	20040309 <--
EP 1608646	A1	20051228	EP 2004-718646	20040309
EP 1608646	B1	20070711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008888	A	20060411	BR 2004-8888	20040309
JP 2006522037	T	20060928	JP 2006-504602	20040309
EP 1760081	A1	20070307	EP 2006-22891	20040309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV				
US 20060211692	A1	20060921	US 2005-551670	20050930
IN 2005KN02182	A	20060929	IN 2005-KN2182	20051103
PRIORITY APPLN. INFO.:				
			DE 2003-10315377	A 20030403
			DE 2003-10327428	A 20030618
			DE 2003-10329295	A 20030630
			DE 2003-10329457	A 20030701
			DE 2003-10334174	A 20030726
			EP 2004-718646	A3 20040309
			WO 2004-EP2405	W 20040309
OTHER SOURCE(S): GI		CASREACT 141:314626; MARPAT 141:314626		



**AB** The invention relates to a method for the production of title compds., e.g. (I), and intermediate products, e.g. (II) for the production of I. Thus, cis-hydroxy-D-proline was reacted with 4-chlorophenylisocyanate in NaHCO<sub>3</sub> at 80° for 5 h. to give after workup 81.8% (R,R)-II. II was then reacted with 4-(3-oxo-4-morpholinyl)aniline in THF with 2-ethoxy-1(2H)-quinoliniccarboxylic acid Et ester (EEDQ) as coupling agent at room temperature for 20 h to give, after workup, 69% (R,R)-I.

**IT** 768370-75-8P 768370-91-8P 768370-94-1P  
768370-99-6P 768371-04-6P 768371-10-4P  
768371-14-8P 768371-19-3P 768371-23-9P  
768371-27-3P 768371-31-9P 768371-35-3P  
768371-38-6P 768371-42-2P 768371-48-8P  
768371-51-3P 768371-54-6P 768371-59-1P  
768371-65-9P 768371-67-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)


(preparation of substituted Ph 1,2-pyrrolidinedicarboxylic acid diamides and intermediates)

**RN** 768370-75-8 HCAPLUS

**CN** 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 768370-91-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-94-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 768370-99-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 768371-04-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-10-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 768371-14-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 768371-19-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-23-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)-3-(trifluoromethyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-27-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-31-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-azido-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-35-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-38-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-42-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetyloxy)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-48-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-oxo-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-51-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-54-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-59-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-65-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propen-1-yloxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-67-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propyn-1-yloxy)-, (2R, 4R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 6 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:857551 HCPLUS

DOCUMENT NUMBER: 141:350179

TITLE: Preparation of azolidinedicarboxamides and related compounds as Factor Xa and Factor VIIa inhibitors

INVENTOR(S): Tsaklakidis, Christos; Dorsch, Dieter; Mederski, Werner; Cezanne, Bertram; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: PCT Int. Appl., 162 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087646	A2	20041014	WO 2004-EP2350	20040308 <--
WO 2004087646	A3	20050106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
 TD, TG  
 DE 10315377 A1 20041014 DE 2003-10315377 20030403 <--  
 DE 10329295 A1 20050203 DE 2003-10329295 20030630  
 AU 2004226278 A1 20041014 AU 2004-226278 20040308 <--  
 CA 2521069 A1 20041014 CA 2004-2521069 20040308 <--  
 BR 2004008420 A 20060321 BR 2004-8420 20040308  
 JP 2006522033 T 20060928 JP 2006-504581 20040308  
 EP 1720844 A2 20061115 EP 2004-718299 20040308  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV  
 RU 2337099 C2 20081027 RU 2005-133870 20040308  
 IN 2005KN01684 A 20070727 IN 2005-KN1684 20050823  
 US 20060183739 A1 20060817 US 2005-551557 20051003  
 PRIORITY APPLN. INFO.: DE 2003-10315377 A 20030403  
 DE 2003-10329295 A 20030630  
 US 2003-483897P P 20030702  
 WO 2004-EP2350 W 20040308

OTHER SOURCE(S): MARPAT 141:350179  
 GI



AB R1R2(TYX)EWCODD [R1, R2 = H, O, halo, A, ethynyl, OR3, N(R3)2, NO2, cyano, N3, CO2R3, CON(R3)2, etc.; R3 = H, A, HC.tplbond.CCH2, MeC.tplbond.CCH2, CH2CH(OH)CH2OH, etc.; R4 = H, A; W = N, C, CR3; E = atoms to form a 3-7 membered (heterocyclic) ring optionally containing a double bond; D = mono- or dinuclear (substituted) (hetero)aryl; G = [C(R4)2]n, [C(R4)2]nNR3, [C(R4)2]nO, [C(R4)2]nS, etc.; n = 0-2; X = [C(R4)2]nCO[C(R4)2]n, [C(R4)2]n, NR3[C(R4)2]n, [C(R4)2]nNR3CO[C(R4)2]n, etc.; Y = alkylene, cycloalkylene, heterocyclylene, arenediyl; T = substituted mono- or dinuclear carbocyclyl, heterocyclyl; A = (fluoro-substituted) alkyl optionally interrupted by O, S, CH:CH], were prepared. Thus, title compound (I) [preparation from 4-(4-aminophenyl)morpholin-3-one, Boc-D-proline, and 4-chlorophenyl isocyanate given] bound to Factor Xa receptors with IC50 = 1.8 + 10-8 M.

IT 536747-22-5P 536748-46-6P 768370-75-8P  
 768370-91-8P 768370-94-1P 768370-99-6P  
 768371-04-6P 768371-10-4P 768371-14-8P  
 768371-19-3P 768371-23-9P 768371-27-3P  
 768371-31-9P 768371-35-3P 768371-38-6P  
 768371-42-2P 768371-48-8P 768371-51-3P

768371-59-1P 768371-65-9P 768371-67-1P  
 773888-70-3P 773888-71-4P 773889-01-3P  
 773889-02-4P 773889-03-5P 773889-04-6P  
 773889-05-7P 773889-06-8P 773889-07-9P  
 773889-08-0P 773889-09-1P 773889-10-4P  
 773889-11-5P 773889-12-6P 773889-13-7P  
 773889-14-8P 773889-15-9P 773889-16-0P  
 773889-17-1P 773889-27-3P 774601-40-0P  
 774601-41-1P 774601-42-2P 774601-45-5P  
 774601-46-6P 774601-47-7P 774601-48-8P  
 774601-51-3P 774601-52-4P 774601-53-5P  
 774601-54-6P 774601-55-7P 774601-56-8P  
 774601-57-9P 774601-58-0P 774601-61-5P  
 774601-62-6P 774601-73-9P 774601-74-0P  
 774601-75-1P 774601-76-2P 774601-77-3P  
 774601-78-4P 774601-79-5P 774601-84-2P  
 774601-85-3P 774601-86-4P 774601-87-5P  
 774601-88-6P 774601-89-7P 774601-90-0P  
 774601-91-1P 774601-92-2P 774601-93-3P  
 774601-94-4P 774601-96-6P 774601-97-7P  
 774601-98-8P 774601-99-9P 774602-00-5P  
 774602-48-1P 774602-49-2P 774602-50-5P  
 774602-51-6P 774602-52-7P 774602-53-8P  
 774602-54-9P 774602-55-0P 774602-58-3P  
 774602-59-4P 774602-60-7P 774602-61-8P  
 774602-73-2P 774602-74-3P 774602-75-4P  
 774602-79-8P 775347-83-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azolidinedicarboxamides and related compds. as Factor Xa and Factor VIIa inhibitors)

RN 536747-22-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536748-46-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 768370-75-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-91-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 768370-94-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 768370-99-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-04-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 768371-10-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 768371-14-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-19-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 768371-23-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)-3-(trifluoromethyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 768371-27-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-31-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-azido-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 768371-35-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 768371-38-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-42-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetyloxy)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 768371-48-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-oxo-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 768371-51-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-59-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-65-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propen-1-yloxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-67-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propyn-1-yloxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773888-70-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773888-71-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 773889-01-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4,4-dimethoxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-02-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-03-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 773889-04-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-hydroxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-05-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-3-hydroxy-, (2R, 3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-06-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-3-hydroxy-, (2R, 3S)- (CA INDEX NAME)


Absolute stereochemistry.

10594024



RN 773889-07-9 HCPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-3,4-dihydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 773889-08-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-azido-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-09-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-

10594024

morpholinyl)phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-10-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetylamino)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R, 4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-11-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetylamino)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R, 4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-12-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-

10594024

[ (methylsulfonyl)amino]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-13-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[ (methylsulfonyl)amino]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-14-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-15-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-propoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-16-0 HCPLUS

CN Propanoic acid, 2-methyl-, (3R,5R)-1-[(4-chlorophenyl)amino]carbonyl]-5-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-3-pyrrolidinyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-17-1 HCPLUS

10594024

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(1-oxoproxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-27-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethynyl-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-40-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetylamino)-N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-41-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-[ (butylsulfonyl)amino]-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-42-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 774601-45-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[3-methyl-4-

10594024

(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-46-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-47-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 774601-48-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[ (2-methyl-1-

10594024

oxopropyl)amino]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-51-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-52-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-53-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-54-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethynyl-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 774601-55-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethynyl-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

10594024


Absolute stereochemistry.



RN 774601-56-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4,4-difluoro-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-57-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 774601-58-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

10594024


Absolute stereochemistry.



RN 774601-61-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-methoxy-2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-62-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-methoxy-2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 774601-73-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-74-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-75-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(2-butyn-1-yloxy)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 774601-76-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-(2,3-dihydroxypropoxy)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-77-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[2-hydroxy-3-(1-pyrrolidinyl)propoxy]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-78-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-[(2-oxo-5-oxazolidinyl)methoxy]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-79-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(3-amino-2-hydroxypropoxy)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-84-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-3-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 774601-85-3 HCAPLUS

CN Benzoic acid, 2-[[[(2R,3R)-1-[(4-chlorophenyl)amino]carbonyl]-3-hydroxy-2-pyrrolidinyl]carbonyl]amino]-5-(3-oxo-4-morpholinyl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-86-4 HCAPLUS

CN Benzoic acid, 2-[[[(2R,3R)-1-[(4-chlorophenyl)amino]carbonyl]-3-hydroxy-2-pyrrolidinyl]carbonyl]amino]-5-(3-oxo-4-morpholinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 774601-87-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-3,4-dihydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 774601-88-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propen-1-yloxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-89-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propyn-1-yloxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-90-0 HCPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propyn-1-yloxy)-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 774601-91-1 HCPLUS  
 CN Acetic acid, 2-[(3R,5R)-1-[(4-chlorophenyl)amino]carbonyl]-5-[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-3-pyrrolidinyl]oxy]-, methyl ester  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 774601-92-2 HCPLUS  
 CN Acetic acid, 2-[(3R,5R)-1-[(4-chlorophenyl)amino]carbonyl]-5-[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-3-pyrrolidinyl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 774601-93-3 HCPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-bromophenyl)-N2-[2-fluoro-4-(3-oxo-4-

10594024

morpholinyl)phenyl]-4-methoxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-94-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-(2,3-dihydroxypropoxy)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-96-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-97-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-imino-1-pyrrolidinyl)-3-methylphenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-98-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-imino-5-methyl-3(2H)-thiazolyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 774601-99-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2-(aminocarbonyl)-4-(3-oxo-4-morpholinyl)phenyl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-00-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-2-methyl-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-48-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(tetrahydro-5-oxo-1,4-oxazepin-4(5H)-yl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-49-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(tetrahydro-5-oxo-1,4-oxazepin-4(5H)-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-50-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[2S]-2-methyl-3-oxo-4-morpholinyl]phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 774602-51-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[2S]-2-methyl-3-

10594024

oxo-4-morpholinyl]phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-52-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[(2R)-2-methyl-3-oxo-4-morpholinyl]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-53-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2R)-2-methyl-3-oxo-4-morpholinyl]phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-54-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)-2-phenoxyphenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-55-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[(2R)-2-methyl-3-oxo-4-morpholinyl]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 774602-58-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-(2-methoxyethoxy)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-59-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(tetrahydro-3-oxo-1,4-oxazepin-4(5H)-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-60-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2-methyl-4-(tetrahydro-3-oxo-1,4-oxazepin-4(5H)-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-61-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-73-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[2-[2-(dimethylamino)ethoxy]-4-morpholinyl]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 774602-74-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-ethoxy-4-morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-75-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-propoxy-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-79-8 HCPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 775347-83-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2E)-2-(cyanoimino)-1-imidazolidinyl]phenyl]-4-hydroxy-, (2R,4R)-(9CI) (CA INDEX NAME)




IT 773889-50-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of azolidinedicarboxamides and related compds. as Factor Xa and Factor VIIa inhibitors)

RN 773889-50-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[(4-nitrobenzoyl)oxy]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)-(CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:841766 HCAPLUS

DOCUMENT NUMBER: 141:332202

TITLE: Preparation of azolidinecarboxamides as antithrombotics and anticancer drugs.

INVENTOR(S): Tsaklakidis, Christos; Dorsch, Dieter; Mederski, Werner; Cezanne, Bertram; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: Ger. Offen., 47 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 5


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10315377	A1	20041014	DE 2003-10315377	20030403 <--
AU 2004226278	A1	20041014	AU 2004-226278	20040308 <--
CA 2521069	A1	20041014	CA 2004-2521069	20040308 <--
WO 2004087646	A2	20041014	WO 2004-EP2350	20040308 <--
WO 2004087646	A3	20050106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2004008420	A	20060321	BR 2004-8420	20040308

CN 1771237	A	20060510	CN 2004-80009354	20040308
JP 2006522033	T	20060928	JP 2006-504581	20040308
EP 1720844	A2	20061115	EP 2004-718299	20040308
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV				
RU 2337099	C2	20081027	RU 2005-133870	20040308
AU 2004226280	A1	20041014	AU 2004-226280	20040309 <--
AU 2004226281	A1	20041014	AU 2004-226281	20040309 <--
CA 2520893	A1	20041014	CA 2004-2520893	20040309 <--
CA 2520894	A1	20041014	CA 2004-2520894	20040309 <--
WO 2004087695	A1	20041014	WO 2004-EP2405	20040309 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004087696	A1	20041014	WO 2004-EP2407	20040309 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1608645	A1	20051228	EP 2004-718641	20040309
EP 1608645	B1	20070502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
EP 1608646	A1	20051228	EP 2004-718646	20040309
EP 1608646	B1	20070711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008444	A	20060404	BR 2004-8444	20040309
BR 2004008888	A	20060411	BR 2004-8888	20040309
CN 1771248	A	20060510	CN 2004-80009374	20040309
CN 1771249	A	20060510	CN 2004-80009463	20040309
JP 2006522037	T	20060928	JP 2006-504602	20040309
JP 2006522038	T	20060928	JP 2006-504604	20040309
AT 361296	T	20070515	AT 2004-718641	20040309
AT 366732	T	20070815	AT 2004-718646	20040309
ES 2285444	T3	20071116	ES 2004-718641	20040309
ES 2287708	T3	20071216	ES 2004-718646	20040309
IN 2005KN01684	A	20070727	IN 2005-KN1684	20050823
US 20060211692	A1	20060921	US 2005-551670	20050930
US 20060183739	A1	20060817	US 2005-551557	20051003
US 20060183742	A1	20060817	US 2005-551559	20051003
IN 2005KN02182	A	20060929	IN 2005-KN2182	20051103

IN 2005KN02183 PRIORITY APPLN. INFO.:	A	20070323	IN 2005-KN2183 DE 2003-10315377 DE 2003-10327428 DE 2003-10329295 DE 2003-10329457 US 2003-483897P DE 2003-10334174 DE 2003-10336570 WO 2004-EP2350 WO 2004-EP2405 WO 2004-EP2407	20051103 A 20030403 A 20030618 A 20030630 A 20030701 P 20030702 A 20030726 A 20030808 W 20040308 W 20040309 W 20040309
--	---	----------	---	--

OTHER SOURCE(S) : MARPAT 141:332202  
GI



AB R1R2(TYX)EWCQGD [R1, R2 = H, O, halo, A, ethynyl, OR3, NO2, cyano, N3, CO2R3, CON(R3)2, NR3COA, NR3SO2A, etc.; R1R2 = toms to form a bicyclic or spirocyclic (heterocyclic) ring; R3 = H, A, etc.; R4 = H, A; W = N, CR3, C; E = atoms to form a 3-7 membered (double bond containing) (heterocyclic) ring with W; G = [C(R4)2]n, [C(R4)2]nNR3, [C(R4)2]nO, [C(R4)2]nS; X = [C(R4)2]nCONR3[C(R4)2]n, [C(R4)2]nON[C(R4)2]n, etc.; Y = alkylene, cycloalkylene, (substituted) heterocyclylene, arylene; T = mono- or bicyclic substituted (unsatd.) (hetero)cyclyl; A = (fluoro-substituted) alkylene optionally interrupted by O, S, CH:CH; n = 0-2], were prepared. Thus, title compound (I) (prepared from 4-(4-aminophenyl)morpholin-3-one, Boc-D-proline, and 4-chlorophenyl isocyanate), bound to Factor Xa receptors with IC50 = 1.8 + 10-8 M.

IT 768370-75-8P 768370-91-8P 768370-94-1P  
768370-99-6P 768371-04-6P 768371-10-4P  
768371-14-8P 768371-19-3P 768371-23-9P  
768371-27-3P 768371-31-9P 768371-35-3P  
768371-38-6P 768371-42-2P 768371-65-9P  
773888-70-3P 773888-71-4P 773889-01-3P  
773889-02-4P 773889-03-5P 773889-04-6P  
773889-05-7P 773889-06-8P 773889-07-9P  
773889-08-0P 773889-09-1P 773889-10-4P  
773889-11-5P 773889-12-6P 773889-13-7P  
773889-14-8P 773889-15-9P 773889-16-0P  
773889-17-1P 773889-27-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of azolidinecarboxamides as antithrombotics and anticancer drugs)


RN 768370-75-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-

10594024

morpholinyl)phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-91-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-94-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 768370-99-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R, 4R)- (CA INDEX NAME)

10594024


Absolute stereochemistry.



RN 768371-04-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-10-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-14-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-19-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-23-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)-3-(trifluoromethyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-27-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-31-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-azido-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-35-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-38-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-42-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetyloxy)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-65-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propen-1-yloxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773888-70-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773888-71-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-01-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4,4-dimethoxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-02-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 773889-03-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-04-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-hydroxy-, (2R, 4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-05-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-3-hydroxy-, (2R, 3R)- (CA INDEX NAME)

Absolute stereochemistry.


10594024



RN 773889-06-8 HCPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-3-hydroxy-, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 773889-07-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-3,4-dihydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 773889-08-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-azido-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-

10594024

morpholinyl)phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-09-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-10-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetylamino)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R, 4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-11-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetylamino)-N1-(4-chlorophenyl)-N2-[4-(3-

10594024

oxo-4-morpholinyl)phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-12-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[ (methylsulfonyl)amino]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R, 4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-13-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[ (methylsulfonyl)amino]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-14-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-15-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-propoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-16-0 HCPLUS

CN Propanoic acid, 2-methyl-, (3R,5R)-1-[(4-chlorophenyl)amino]carbonyl]-5-

10594024

[[(4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-3-pyrrolidinyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-17-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(1-oxopropoxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-27-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethynyl-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 773889-50-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of azolidinecarboxamides as antithrombotics and anticancer drugs)

RN 773889-50-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[(4-nitrobenzoyl)oxy]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 4 OF 6 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:799558 HCPLUS

DOCUMENT NUMBER: 141:296012

TITLE: Preparation of factor Xa- and thrombin-inhibiting substituted benzamidines and sulfonylbenzamidines as potential anticoagulants

INVENTOR(S): Pinto, Donald J.; Qiao, Jennifer X.; Gangor, Timur;

Lam, Patrick Y. S.; Li, Yun-long

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 279 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083174	A2	20040930	WO 2004-US8033	20040317 <--
WO 2004083174	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040209863	A1	20041021	US 2004-801518	20040316 <--
US 7122557	B2	20061017		
EP 1603562	A2	20051214	EP 2004-757516	20040317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRIORITY APPLN. INFO.: US 2003-455709P P 20030318 US 2004-801518 A 20040316 WO 2004-US8033 W 20040317				

OTHER SOURCE(S): MARPAT 141:296012  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Compds. P4-M-M4 (I) [M = (un)substituted 3-10 membered carbocyclic or a 4-10 membered heterocyclic ring containing 1-3 O, N, or S atoms, alone or fused to an (un)substituted 5-7 membered carbocycle or heterocycle; P4 = Z-A-B; M4 = G-G1; A = (un)substituted 3-10 membered carbocyclic or 5-12 membered heterocyclic ring ; B = (un)substituted amidino, guanidino, iminomethyl; G = five or six-membered carbocycle or heterocycle fused to a benzene, pyridine, pyrimidine, pyrazine, or pyridazine ring; G1 = bond, (un)substituted alkyl, alkenyl, alkynyl; Z = (un)substituted alkylene], such as tetrahydropyrazolo[3,4-c]pyridinone II or (pyridinylaminocarbonylphenylaminocarbonyl)benzamidine III are prepared as inhibitors of Factor Xa and thrombin for use as anticoagulants. Deprotonation of 2-amino-4-chloropyridine and addition to 5-chloroisatoic anhydride yields N-(5-chloro-2-pyridinyl) 2-amino-5-chlorobenzamide (IV). Acid-mediated addition of dimethylamine to the nitrile of Me 4-cyanobenzoate, mesylation of the amidine nitrogen, and base-mediated hydrolysis of the ester yields 4-(N,N-dimethyl-N'-methylsulfonylamidino)benzoic acid (V). Coupling of IV and V mediated by BOP yields III. Some compds. of the invention inhibit human factor Xa with Ki values of  $\leq 10 \mu\text{M}$ ; in addition, some of the invention compds. inhibit thrombin in vitro. (no data).

10594024

IT 764658-81-3P 764658-82-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of factor Xa- and thrombin-inhibiting substituted benzamidines and sulfonylbenzamidines as potential anticoagulants)

RN 764658-81-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(E)-[(methylsulfonyl)imino]-1-pyrrolidinylmethyl]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 764658-82-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(dimethylamino)[(methylsulfonyl)imino]methyl]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



L9 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:434528 HCAPLUS

DOCUMENT NUMBER: 139:6763


TITLE: Preparation of pyrrolidinedicarboxamides and related compounds as inhibitors of factor Xa useful for

INVENTOR(S): thrombotic disorders  
Bigge, Christopher Franklin; Dudley, Danette Andrea;  
Edmunds, Jeremy John; Van Huis, Chad Alan;  
Casimiro-Garcia, Agustin; Filipski, Kevin James;  
Kohrt, Jeffrey Thomas  
PATENT ASSIGNEE(S): Warner-Lambert Company L.L.C., USA  
SOURCE: PCT Int. Appl., 389 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045912	A1	20030605	WO 2002-IB4757	20021114 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030162787	A1	20030828	US 2002-278643	20021023 <--
US 7030141	B2	20060418		
CA 2468715	A1	20030605	CA 2002-2468715	20021114 <--
AU 2002365313	A1	20030610	AU 2002-365313	20021114 <--
AU 2002365313	B2	20080306		
BR 2002014519	A	20041013	BR 2002-14519	20021114 <--
EP 1465864	A1	20041013	EP 2002-803885	20021114 <--
EP 1465864	B1	20060315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1582274	A	20050216	CN 2002-823837	20021114
HU 2004002529	A2	20050329	HU 2004-2529	20021114
JP 2005515985	T	20050602	JP 2003-547364	20021114
AT 320414	T	20060415	AT 2002-803885	20021114
EP 1671949	A2	20060621	EP 2006-110738	20021114
EP 1671949	A3	20060719		
EP 1671949	B1	20080723		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PT 1465864	T	20060630	PT 2002-803885	20021114
ES 2259113	T3	20060916	ES 2002-803885	20021114
NZ 532384	A	20061027	NZ 2002-532384	20021114
AP 1744	A	20070630	AP 2004-3035	20021114
AT 402148	T	20080815	AT 2006-110738	20021114
MX 2004PA03606	A	20040727	MX 2004-PA3606	20040416 <--
ZA 2004004085	A	20050905	ZA 2004-4085	20040525
NO 2004002270	A	20040601	NO 2004-2270	20040601 <--
US 20050267118	A1	20051201	US 2004-17598	20041220
US 7407972	B2	20080805		
US 20050250815	A1	20051110	US 2005-108582	20050418
US 7407974	B2	20080805		

US 20060264626 PRIORITY APPLN. INFO.:	A1      20061123	US 2006-461859 US 2001-334168P US 2002-384895P US 2002-278643 EP 2002-803885 WO 2002-IB33416 WO 2002-IB4757 US 2004-17598	20060802 P 20011129 P 20020531 A3 20021023 A3 20021114 A 20021114 W 20021114 A3 20041220
--	------------------	--	---

OTHER SOURCE(S): MARPAT 139:6763  
GI



AB The present invention provides pyrrolidinedicarboxamides and related compds. (shown as I; variables defined below; e.g. (R)-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide]) and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compns. comprising  $\geq 1$  compds. I, processes for preparing I, and intermediates useful for preparing I. IC<sub>50</sub> values for inhibition of factor Xa are tabulated for >170 examples of I. About 180 example preps. of I are included. For example, (R)-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] was prepared in 4 steps starting from Fmoc-D-Pro, SOC<sub>12</sub>, and 4-bromo-2-fluoroaniline and involving intermediates (R)-2-[(4-bromo-2-fluorophenyl)carbamoyl]pyrrolidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester, (R)-pyrrolidine-2-carboxylic acid (2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide, and (R)-pyrrolidine-1,2-dicarboxylic acid 2-[(2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide] 1-[(4-chlorophenyl)amide] with yields of 99, 70, 66 and 76%, resp. Four pharmaceutical formulations are described. For I: A is (un)substituted aryl or (un)substituted monocyclic heteroaryl; B is -NHC(O)(C<sub>1</sub>-C<sub>6</sub>)alkyl, -NHC(O)(C<sub>3</sub>-C<sub>7</sub>)cycloalkyl, -NHC(O)O(C<sub>1</sub>-C<sub>6</sub>)alkyl, -C(O)R<sub>1</sub>, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)heterocyclo, (C<sub>4</sub>-C<sub>7</sub>)cycloalkenyl, unsatd. (C<sub>4</sub>-C<sub>7</sub>)heterocyclo, aryl, or heteroaryl, any of which may be (un)substituted by halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, O(C<sub>1</sub>-C<sub>6</sub>), -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido. C is Ph or heteroaryl, wherein Ph or heteroaryl is (un)substituted with  $\geq 1$  substituents = aryl, heteroaryl, halogen, hydroxy, -CO<sub>2</sub>R<sub>2</sub>, -COR<sub>2</sub>, -CONR<sub>2</sub>R<sub>2'</sub>, alkoxy, alkyl, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido; G is H, halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, -CH<sub>2</sub>O(C<sub>1</sub>-C<sub>6</sub>)alkyl, -CH<sub>2</sub>CO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, -CH<sub>2</sub>NR<sub>2</sub>R<sub>2'</sub>, or -CH<sub>2</sub>C(O)NH(C<sub>1</sub>-C<sub>6</sub>)alkyl. W<sub>1</sub> is a saturated or unsatd., (un)substituted hydrocarbon chain or hydrocarbon-heteroatom chain having 2-6 atoms, wherein W<sub>1</sub> connects the N atom at position 1 to the C atom at position 2 to form a four to eight membered ring; R<sub>1</sub> is (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)heterocycloalkyl, (C<sub>4</sub>-C<sub>7</sub>)cycloalkenyl, (C<sub>4</sub>-C<sub>7</sub>)heterocycloalkenyl, aryl, monocyclic heteroaryl, or -NR<sub>3</sub>R<sub>4</sub>; R<sub>2</sub> and


R2' are each independently H or (C1-C6)alkyl; and R3 and R4 are each independently H, (C1-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxy carbonyl, aralkoxy carbonyl, -SO<sub>2</sub>alkyl, or joined together to form a saturated or unsatd. 3 to 7 membered ring.

IT 536746-63-1P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536746-77-7P, Pyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(4-cyanophenyl)amide]  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)

RN 536746-63-1 HCPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy-, (2R, 4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536746-77-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-(4-cyanophenyl)- (CA INDEX NAME)



IT 536746-25-5P, (R)-Pyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide]  
 536746-29-9P, Pyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide]  
 536746-36-8P, Pyrrolidine-1,2-dicarboxylic acid  
 1-[(2,4-difluorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-  
 yl)amide] 536746-38-0P, Pyrrolidine-1,2-dicarboxylic acid  
 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 1-[(4-methoxyphenyl)amide]  
 536746-39-1P, Pyrrolidine-1,2-dicarboxylic acid  
 1-[(4-bromophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide]  
 536746-42-6P, Pyrrolidine-1,2-dicarboxylic acid  
 1-[(3,4-difluorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-  
 yl)amide] 536746-49-3P, Pyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-  
 yl)amide] 536746-60-8P, Pyrrolidine-1,2-dicarboxylic acid  
 2-[(3-chloro-2'-methanesulfonylbiphenyl-4-yl)amide]  
 1-[(4-chlorophenyl)amide] 536746-74-4P,  
 Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[(4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl)amide]  
 536746-75-5P, Pyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(4-(1-methyl-4,5-dihydro-1H-imidazol-2-  
 yl)phenyl)amide] trifluoroacetate 536746-78-8P,  
 Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[(2'-methanesulfonylbiphenyl-4-yl)amide] 536746-82-4P,  
 Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[(2'-methanesulfonyl-3-methylbiphenyl-4-yl)amide] 536746-87-9P  
 , (2R,4R)-4-Methoxypyrrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-  
 yl)amide] 536746-88-0P, (2R)-4-Oxopyrrolidine-1,2-dicarboxylic  
 acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-  
 yl)amide] 536746-89-1P, (2R,4S)-4-Fluoropyrrolidine-1,2-  
 dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536746-91-5P  
 , (2R,4R)-4-Hydroxypyrrrolidine-1,2-dicarboxylic acid  
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide]  
 1-[(4-fluorophenyl)amide] 536746-93-7P,  
 Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[(2'-methanesulfonyl-3-trifluoromethylbiphenyl-4-yl)amide]  
 536746-98-2P, (2R,4R)-4-Methoxypyrrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-  
 yl)phenyl]amide] 536747-05-4P,  
 (2R,4R)-4-Hydroxypyrrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[4-(2-oxopiperidin-1-yl)phenyl]amide]  
 536747-06-5P, (2R,4R)-4-Hydroxypyrrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-  
 yl)phenyl]amide] 536747-10-1P,  
 (2R,4R)-4-Ethoxypyrrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-  
 yl)phenyl]amide] 536747-11-2P,  
 (2R,4R)-4-Propoxypyrrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-  
 yl)phenyl]amide] 536747-13-4P,  
 (2R,4R)-4-Cyanopyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536747-14-5P,  
 (2R,4R)-4-Fluoropyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-  
 yl)phenyl]amide] 536747-15-6P,

(2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxoazetidin-1-yl)phenyl]amide]  
 536747-17-8P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopyrrolidin-1-  
 yl)phenyl]amide] 536747-19-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxoazepan-1-yl)phenyl]amide]  
 536747-22-5P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(2-oxo-1,2-dihydropyridin-1-  
 yl)phenyl]amide] 536747-23-6P,  
 (2R, 4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-1,2-dihydropyridin-1-  
 yl)phenyl]amide] 536747-25-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-((2S)-2-hydroxymethyl-5-  
 oxopyrrolidin-1-yl)phenyl]amide] 536747-26-9P,  
 (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(2,3-dimethyl-5-oxo-2,5-dihydropyrazol-1-  
 yl)phenyl]amide] 536747-27-0P,  
 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[ (4-chlorophenyl)amide]  
 2-[[4-(2-hydroxymethylpyrrolidin-1-yl)phenyl]amide] 536747-28-1P  
 , (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-(pyrrolidin-1-yl)phenyl)amide]  
 536747-29-2P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-(pyrazol-1-yl)phenyl)amide]  
 536747-30-5P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2-fluoro-4-(pyrazol-1-yl)phenyl)amide]  
 536747-31-6P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-[1,2,4]triazol-1-ylphenyl)amide]  
 536747-32-7P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-[1,2,3]triazol-2-ylphenyl)amide]  
 536747-33-8P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-[1,2,3]triazol-1-ylphenyl)amide]  
 536747-34-9P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 2-[(4-acetylaminophenyl)amide] 1-[ (4-chlorophenyl)amide]  
 536747-35-0P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-[(cyclopentanecarbonyl)amino]phenyl]amide]  
 536747-36-1P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-pyrimidin-5-ylphenyl)amide]  
 536747-37-2P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-(pyrazol-1-yl)phenyl)amide]  
 536747-38-3P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2-fluoro-4-(pyrazol-1-yl)phenyl)amide]  
 536747-39-4P, (2R, 4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2-fluoro-4-(pyrazol-1-yl)phenyl)amide]  
 536747-40-7P, (2R, 4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-(pyrazol-1-yl)phenyl)amide]  
 536747-41-8P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methylpyrazol-1-  
 yl)phenyl]amide] 536747-46-3P,  
 (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methylpyrazol-1-  
 yl)phenyl]amide] 536747-47-4P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methylpyrazol-1-  
 yl)phenyl]amide] 536747-48-5P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid

1-[(4-chlorophenyl)amide] 2-[[4-(5-methylpyrazol-1-yl)phenyl]amide]  
 536747-49-6P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[4-(3,5-dimethylpyrazol-1-yl)phenyl]amide]  
 536747-50-9P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[4-(3,5-dimethylpyrazol-1-yl)phenyl]amide]  
 536747-51-0P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[4-(3,5-dimethylpyrazol-1-yl)-2-fluorophenyl]amide] 536747-53-2P,  
 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 2-[(4-tert-butylphenyl)amide]  
 1-[(4-chlorophenyl)amide] 536747-54-3P,  
 (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3,5'-difluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536747-61-2P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[[4-(2,3-dimethyl-5-oxo-2,5-dihydropyrazol-1-yl)phenyl]amide]  
 536747-68-9P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-oxo-6H-pyridazin-1-yl)phenyl]amide] 536747-70-3P,  
 (2R,4S)-4-Aminopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-73-6P,  
 , (2R,4R)-4-Aminopyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-75-8P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536747-76-9P,  
 (2R)-4-Hydroxyiminopyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-77-0P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[(3-fluoro-2'-methylsulfamoylbiphenyl-4-yl)amide] 536747-78-1P,  
 , (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(2'-dimethylsulfamoyl-3-fluorobiphenyl-4-yl)amide] 536747-80-5P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536747-82-7P,  
 (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-83-8P, (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536747-84-9P,  
 (2R,4S)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-85-0P, (2R,4R)-4-Fluoropyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-86-1P,  
 , (2R)-4,4-Difluoropyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-88-3P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide]  
 1-[(4-fluorophenyl)amide] 536747-89-4P,  
 (2R,4R)-4-Acetylaminopyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-90-7P, (2R,4R)-4-Methanesulfonylaminopyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-91-8P, (2R,4S)-4-(1H-Tetrazol-5-yl)pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]

2-[ [2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536747-92-9P,  
 (2R, 4S)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-oxopiperidin-1-  
 yl)phenyl]amide] 536747-93-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-methylimidazol-1-  
 yl)phenyl]amide] 536747-94-1P,  
 (2R, 4R)-4-(1H-Tetrazol-5-yl)pyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-oxopiperidin-1-  
 yl)phenyl]amide] 536747-95-2P,  
 (2R, 4R)-4-Trifluoromethylpyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-oxopiperidin-1-  
 yl)phenyl]amide] 536747-96-3P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ (2'-cyano-3-fluorobiphenyl-4-yl)amide]  
 536747-97-4P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ (2'-aminomethyl-3-fluorobiphenyl-4-yl)amide] 1-[ (4-chlorophenyl)amide]  
 536747-98-5P, (2R, 4R)-4'-[ [1-[ (4-Chlorophenyl)carbamoyl]-4-  
 methoxypyrrolidine-2-carbonyl]amino]-3'-fluorobiphenyl-2-carboxylic acid  
 methyl ester 536747-99-6P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(2,5-dihydropyrrole-1-  
 carbonyl)phenyl]amide] 536748-04-6P,  
 (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ (4-dimethylcarbamoyl-2-fluorophenyl)amide]  
 536748-09-1P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(pyrrolidine-1-carbonyl)phenyl]amide]  
 536748-10-4P, Pyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(pyrrolidine-1-carbonyl)phenyl]amide]  
 536748-11-5P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(2-methylpyrrolidine-1-  
 carbonyl)phenyl]amide] 536748-12-6P,  
 (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-[ (ethylmethyl)carbamoyl]phenyl]amide]  
 536748-13-7P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ (4-dimethylcarbamoylphenyl)amide]  
 536748-14-8P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(2R-methylpyrrolidine-1-  
 carbonyl)phenyl]amide] 536748-15-9P,  
 (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(2S-methylpyrrolidine-1-  
 carbonyl)phenyl]amide] 536748-16-0P,  
 (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(pyrrolidine-1-  
 carbonyl)phenyl]amide] 536748-17-1P,  
 (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(pyrrolidine-1-carbonyl)-2-(pyrrolidin-1-  
 yl)phenyl]amide] 536748-18-2P,  
 (2R, 4R)-4-[ [1-[ (4-Chlorophenyl)carbamoyl]-4-hydroxypyrrolidine-2-  
 carbonyl]amino]-3-(pyrrolidin-1-yl)benzoic acid methyl ester  
 536748-19-3P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [4-(azetidine-1-carbonyl)phenyl]amide] 1-[ (4-chlorophenyl)amide]  
 536748-23-9P, (2R, 4R)-4-[ [1-[ (4-Chlorophenyl)carbamoyl]-4-  
 hydroxypyrrolidine-2-carbonyl]amino]-3-dimethylaminobenzoic acid methyl  
 ester 536748-24-0P, (2R, 4R)-4-Methoxypyrrolidine-1,2-  
 dicarboxylic acid 1-[ (4-chlorophenyl)amide]  
 2-[ [4-(pyrrolidine-1-carbonyl)phenyl]amide] 536748-25-1P,

(2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-dimethylcarbamoylphenyl)amide]  
 536748-26-2P, (2R, 4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-(pyrrolidine-1-carbonyl)phenyl)amide]  
 536748-27-3P, (2R, 4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-dimethylcarbamoylphenyl)amide]  
 536748-28-4P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2-fluoro-4-(pyrrolidine-1-carbonyl)phenyl)amide] 536748-29-5P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-dimethylcarbamoyl-2-fluorophenyl)amide]  
 536748-30-8P, (2R, 4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2-fluoro-4-(pyrrolidine-1-carbonyl)phenyl)amide] 536748-31-9P,  
 (2R, 4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(4-dimethylcarbamoyl-2-fluorophenyl)amide]  
 536748-32-0P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2-methyl-4-(2-oxopiperidin-1-yl)phenyl)amide] 536748-33-1P,  
 (2R, 4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2-methyl-4-(2-oxopiperidin-1-yl)phenyl)amide] 536748-34-2P, Pyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2-fluoro-4-quinolin-8-ylphenyl)amide]  
 536748-35-3P, Pyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(3,5-difluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-36-4P, Pyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-2-methylbiphenyl-4-yl)amide] 536748-37-5P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[ (4-chlorophenyl)amide]  
 2-[(2'-methanesulfonylbiphenyl-4-yl)amide] 536748-38-6P,  
 (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2'-methanesulfinylbiphenyl-4-yl)amide]  
 536748-39-7P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(3-methyl-2'-methylsulfanyl)phenylbiphenyl-4-yl)amide] 536748-40-0P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[ (4-chlorophenyl)amide]  
 2-[(2-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-41-1P,  
 (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-3-methylbiphenyl-4-yl)amide] 536748-42-2P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[ (4-chlorophenyl)amide]  
 2-[(2'-methanesulfonyl-3-trifluoromethylbiphenyl-4-yl)amide]  
 536748-43-3P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2'-methoxybiphenyl-4-yl)amide]  
 536748-44-4P, (2R, 4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2'-hydroxybiphenyl-4-yl)amide]  
 536748-45-5P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2-fluoro-4-iodophenyl)amide]  
 536748-46-6P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenyl)amide] 536748-48-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2-fluoro-4-(3-hydroxy-2-oxopiperidin-1-yl)phenyl)amide] 536748-49-9P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[(2-fluoro-4-(2-oxotetrahydropyrimidin-1-yl)phenyl)amide] 536748-50-2P,

(2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxoimidazolidin-1-yl)phenyl]amide] 536748-51-3P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxooxazolidin-3-yl)phenyl]amide] 536748-52-4P,  
 (2R, 4R)-1-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl)amino]-3-fluorophenyl]-2-oxopiperidine-3-carboxylic acid ethyl ester 536748-53-5P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[[2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-55-7P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[4-(3-methyl-2-oxo-1H-pyridin-1-yl)phenyl]amide] 536748-59-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(4-(morpholin-4-yl)phenyl)amide] 536748-60-4P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[4-(2-methyl-5-oxopyrrolidin-1-yl)phenyl]amide] 536748-62-6P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-64-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methyl-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-67-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-methoxy-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-69-3P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-71-7P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-methyl-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-72-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(5-chloro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536748-89-7P,  
 Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(1H-tetrazol-5-yl)phenyl]amide] 536748-90-0P,  
 4-Hydroxypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-91-1P  
 , 4-Methoxypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-92-2P  
 , 4-Oxopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-93-3P  
 , 4-Methyleneypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-94-4P  
 , 4-Methylpyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-95-5P  
 , 4,4-Difluoropyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-96-6P  
 , 4-Aminopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-97-7P  
 , 4-Hydroxymethylpyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-98-8P, 1-[(4-Chlorophenyl)carbamoyl]-5-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)carbamoyl]pyrrolidine-3-carboxylic


acid 536748-99-9P, 1-[(4-Chlorophenyl)carbamoyl]-5-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)carbamoyl]pyrrolidine-3-carboxylic acid methyl ester 536749-00-5P, Pyrrolidine-1,2,4-tricarboxylic acid 4-amide 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-01-6P,  
 4-Aminomethylpyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-02-7P  
 , 4-Methoxymethylpyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-03-8P, 4-Ethoxypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-04-9P, 4-Methylaminopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-05-0P  
 , 4-Acetylaminopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-06-1P  
 , 4-Methanesulfonylaminopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-07-2P, 5-Oxopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-12-9P, 4-Hydroxypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-3-methylbiphenyl-4-yl)amide] 536749-13-0P, 4-Hydroxypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonylbiphenyl-4-yl)amide] 536749-18-5P, 4-Hydroxypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-3-trifluoromethylbiphenyl-4-yl)amide] 536749-21-0P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-ethyl-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-22-1P, 4-Hydroxypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-ethyl-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-23-2P, 4-Hydroxypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5-difluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-24-3P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5-dichloro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-25-4P, 4-Hydroxypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5-dichloro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-26-5P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-3,5-dimethylbiphenyl-4-yl)amide] 536749-27-6P, 4-Hydroxypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-3,5-dimethylbiphenyl-4-yl)amide] 536749-28-7P, Pyrrolidine-1,2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl-5-methylbiphenyl-4-yl)amide]  
 1-[(4-chlorophenyl)amide] 536749-29-8P,  
 4-Hydroxypyrrrolidine-1,2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl-5-methylbiphenyl-4-yl)amide]  
 1-[(4-chlorophenyl)amide] 536749-30-1P,  
 Pyrrolidine-1,2-dicarboxylic acid 2-[(2-chloro-2'-methanesulfonylbiphenyl-4-yl)amide] 1-[(4-chlorophenyl)amide] 536749-31-2P,  
 4-Hydroxypyrrrolidine-1,2-dicarboxylic acid 2-[(2-chloro-2'-methanesulfonylbiphenyl-4-yl)amide]  
 1-[(4-chlorophenyl)amide] 536749-32-3P,  
 4-Hydroxypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-2-methylbiphenyl-4-yl)amide] 536749-33-4P  
 , Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-34-5P  
 , 4-Hydroxypyrrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-35-6P

, 4-[1-[(4-Chlorophenyl)carbamoyl]pyrrolidine-2-carbonyl]amino]-2'-methanesulfonylbiphenyl-3-carboxylic acid methyl ester  
 536749-36-7P, 4-[1-[(4-Chlorophenyl)carbamoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-2'-methanesulfonylbiphenyl-3-carboxylic acid methyl ester 536749-41-4P,  
 Pyrrolidine-1,2-dicarboxylic acid 1-[(3-chloro-4-fluorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-44-7P,  
 Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chloro-2-methylphenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-45-8P,  
 Pyrrolidine-1,2-dicarboxylic acid 1-[(3,4-dichlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-48-1P,  
 (2S)-Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-49-2P,  
 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide]  
 1-[(4-fluorophenyl)amide] 536749-52-7P,  
 4-Fluoropyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-53-8P  
 , (2R,4S)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-54-9P, 1-[(4-Chlorophenyl)carbamoyl]-5-[(2-fluoro-4-(2-oxopiperidin-1-yl)phenyl)carbamoyl]pyrrolidine-3-carboxylic acid 536749-55-0P, 1-[(4-Chlorophenyl)carbamoyl]-5-[(2-fluoro-4-(2-oxopiperidin-1-yl)phenyl)carbamoyl]pyrrolidine-3-carboxylic acid methyl ester 536749-56-1P, 1-[(4-Chlorophenyl)carbamoyl]-5-[(2-fluoro-4-(2-oxopiperidin-1-yl)phenyl)carbamoyl]pyrrolidine-3-carboxylic acid ethyl ester 536749-57-2P, Pyrrolidine-1,2,4-tricarboxylic acid 4-amide 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-58-3P,  
 4-Cyanopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-59-4P,  
 4-(1H-Tetrazol-5-yl)pyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-60-7P,  
 4-Aminomethylpyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-61-8P,  
 4-Methylaminomethylpyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-62-9P,  
 4-Dimethylaminomethylpyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-63-0P,  
 4-Acetylpyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide]  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)

RN 536746-25-5 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536746-29-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)- (CA INDEX NAME)




RN 536746-36-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(2,4-difluorophenyl)- (CA INDEX NAME)




RN 536746-38-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-methoxyphenyl)- (CA INDEX NAME)




RN 536746-39-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-bromophenyl)- (CA INDEX NAME)




RN 536746-42-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(3,4-difluorophenyl)- (CA INDEX NAME)




RN 536746-49-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536746-60-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[3-chloro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)- (CA INDEX NAME)



RN 536746-74-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 536746-75-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 536746-74-4


CMF C22 H24 Cl N5 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



10594024


RN 536746-78-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536746-82-4 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536746-87-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536746-88-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-oxo-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536746-89-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-fluoro-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536746-91-5 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-fluorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536746-93-7 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2'-(methylsulfonyl)-3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536746-98-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-05-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-06-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-10-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-11-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-propoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-13-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-cyano-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-14-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-fluoro-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-15-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-azetidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-17-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-pyrrolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-19-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(hexahydro-2-oxo-1H-azepin-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536747-22-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-23-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-25-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[(2S)-2-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-26-9 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536747-27-0 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[2-(hydroxymethyl)-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)



RN 536747-28-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(1-pyrrolidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-29-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(1H-pyrazol-1-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536747-30-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-31-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-32-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2H-1,2,3-triazol-2-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536747-33-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(1H-

10594024

1,2,3-triazol-1-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-34-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(acetylamino)phenyl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-35-0 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(cyclopentylcarbonyl)amino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536747-36-1 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)



RN 536747-37-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(1H-pyrazol-1-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-38-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536747-39-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-fluoro-4-

10594024

(1H-pyrazol-1-yl)phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-40-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(1H-pyrazol-1-yl)phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-41-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-1H-pyrazol-1-yl)phenyl]-4-methoxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-46-3 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-methyl-1H-pyrazol-1-yl)phenyl]-4-hydroxy-, (2R, 4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536747-47-4 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-methyl-1H-pyrazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536747-48-5 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(5-methyl-1H-pyrazol-1-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536747-49-6 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,5-dimethyl-1H-

10594024

pyrazol-1-yl)phenyl]-4-hydroxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-50-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-4-methoxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-51-0 HCPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,5-dimethyl-1H-pyrazol-1-yl)-2-fluorophenyl]-4-methoxy-, (2R, 4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536747-53-2 HCAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(1,1-dimethylethyl)phenyl]-4-hydroxy- (CA INDEX NAME)




RN 536747-54-3 HCAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3,5'-difluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536747-61-2 HCAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-68-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-oxo-1(6H)-pyridazinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-70-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536747-73-6 HCPLUS

10594024

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-75-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536747-76-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-(hydroxyimino)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 536747-77-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylamino)sulfonyl]-[1,1'-biphenyl]-4-yl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-78-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2'-(dimethylamino)sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-80-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-82-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-83-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N2-(4-chlorophenyl)-4-ethoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-84-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methoxy-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-85-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-fluoro-N2-[3-fluoro-2'-(methylsulfonyl)][1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-86-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4,4-difluoro-N2-[3-fluoro-2'-(methylsulfonyl)][1,1'-biphenyl]-4-yl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-88-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-fluorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-89-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetylamino)-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-90-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-[(methylsulfonyl)amino]-, (2R,4R)-(CA INDEX NAME)


Absolute stereochemistry.



RN 536747-91-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-(2H-tetrazol-5-yl)-, (2R,4S)-(CA INDEX NAME)


Absolute stereochemistry.



RN 536747-92-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methoxy-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-93-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-94-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-(2H-tetrazol-5-yl)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-95-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-(trifluoromethyl)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-96-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-(2'-cyano-3-fluoro[1,1'-biphenyl]-4-yl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-97-4 HCPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminomethyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536747-98-5 HCAPLUS  
 CN [1,1'-Biphenyl]-2-carboxylic acid,  
 4'-([(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-  
 pyrrolidinyl]carbonyl]amino]-3'-fluoro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 536747-99-6 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2,5-dihydro-1H-pyrrol-1-yl)carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536748-04-6 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(dimethylamino)carbonyl]-2-fluorophenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-09-1 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(1-pyrrolidinylcarbonyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536748-10-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(1-pyrrolidinylcarbonyl)phenyl]- (CA INDEX NAME)




RN 536748-11-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[2-

10594024

methyl-1-pyrrolidinyl)carbonyl]phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-12-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[(propylamino)carbonyl]phenyl]-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-13-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(dimethylamino)carbonyl]phenyl]-4-hydroxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-14-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[(2R)-2-methyl-1-pyrrolidinyl]carbonyl]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-15-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[(2S)-2-methyl-1-pyrrolidinyl]carbonyl]phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536748-16-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-methylthioethyl)carbonyl]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

10594024


Absolute stereochemistry.



RN 536748-17-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2-(1-pyrrolidinyl)-4-(1-pyrrolidinylcarbonyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-18-2 HCAPLUS

CN Benzoic acid, 4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-hydroxy-2-(1-pyrrolidinyl)carbonyl]amino]-3-(1-pyrrolidinyl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-19-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(1-azetidinylcarbonyl)phenyl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-23-9 HCAPLUS

CN Benzoic acid, 4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]-3-(dimethylamino)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536748-24-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(1-pyrrolidinylcarbonyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-25-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(dimethylamino)carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-26-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[4-(1-pyrrolidinylcarbonyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536748-27-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(dimethylamino)carbonyl]phenyl]-4-ethoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-28-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-pyrrolidinylcarbonyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-29-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(dimethylamino)carbonyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-30-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-fluoro-4-(1-pyrrolidinylcarbonyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-31-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(dimethylamino)carbonyl]-2-fluorophenyl]-4-ethoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-32-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[2-methyl-4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-33-1 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-methyl-4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536748-34-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(8-quinolinyl)phenyl]- (CA INDEX NAME)




RN 536748-35-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-difluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536748-36-4 HCPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-methyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536748-37-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-38-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2'-(methylsulfinyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-39-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[3-methyl-2'-(methylthio)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-40-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-41-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[3-methyl-2'-(methylsulfonyl)-1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-42-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2'-(methylsulfonyl)-3-(trifluoromethyl)-1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-43-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-(2'-methoxy[1,1'-biphenyl]-4-yl)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-44-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-(2'-hydroxy[1,1'-biphenyl]-4-yl)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-45-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-(2-fluoro-4-iodophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-46-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536748-48-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-

10594024

hydroxy-2-oxo-1-piperidinyl)phenyl]-4-methoxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-49-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)phenyl]-4-methoxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-50-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-imidazolidinyl)phenyl]-4-methoxy-, (2R, 4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536748-51-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-52-4 HCAPLUS

CN 3-Piperidinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-2-oxo-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-53-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methoxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-55-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(3-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-59-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536748-60-4 HCAPLUS

10594024

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(2-methyl-5-oxo-1-pyrrolidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-62-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-64-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536748-67-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-methoxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-69-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-71-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-72-8 HCPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-chloro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536748-89-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2H-tetrazol-5-yl)phenyl]- (CA INDEX NAME)




RN 536748-90-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)




RN 536748-91-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)][1,1'-biphenyl]-4-methoxy- (CA INDEX NAME)




RN 536748-92-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)][1,1'-biphenyl]-4-oxo- (CA INDEX NAME)




RN 536748-93-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methylene- (CA INDEX NAME)




RN 536748-94-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methyl- (CA INDEX NAME)




RN 536748-95-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4,4-difluoro-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536748-96-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536748-97-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-(hydroxymethyl)- (CA INDEX NAME)




RN 536748-98-8 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[[[(4-chlorophenyl)amino]carbonyl]-5-[[[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]- (CA INDEX NAME)




RN 536748-99-9 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[[[4-chlorophenyl)amino]carbonyl]-5-[[[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)




RN 536749-00-5 HCAPLUS

CN 1,2,4-Pyrrolidinetriscarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-01-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(aminomethyl)-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-02-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-(methoxymethyl)- (CA INDEX NAME)




RN 536749-03-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-04-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-(methylamino)- (CA INDEX NAME)




RN 536749-05-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetylamino)-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-06-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-[(methylsulfonyl)amino]- (CA INDEX NAME)




RN 536749-07-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-5-oxo- (CA INDEX NAME)




RN 536749-12-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[3-methyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-13-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-18-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2'-(methylsulfonyl)-3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-21-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-ethyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-22-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-ethyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)




RN 536749-23-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-difluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)




RN 536749-24-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-dichloro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-25-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-dichloro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)




RN 536749-26-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-dimethyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-27-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-dimethyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)




RN 536749-28-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[3-chloro-5-methyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)- (CA INDEX NAME)




RN 536749-29-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[3-chloro-5-methyl-2'-(methylsulfonyl)][1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)




RN 536749-30-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2-chloro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)- (CA INDEX NAME)




RN 536749-31-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2-chloro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)




RN 536749-32-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2-methyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-33-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-34-5 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)



RN 536749-35-6 HCAPLUS  
 CN [1,1'-Biphenyl]-3-carboxylic acid,  
 4-[[[1-[(4-chlorophenyl)amino]carbonyl]-2-pyrrolidinyl]carbonyl]amino]-2'-(methylsulfonyl)-, methyl ester (CA INDEX NAME)




RN 536749-36-7 HCAPLUS  
 CN [1,1'-Biphenyl]-3-carboxylic acid,  
 4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]-2'-(methylsulfonyl)-, methyl ester (CA INDEX NAME)




RN 536749-41-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)




RN 536749-44-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chloro-2-methylphenyl)- (CA INDEX NAME)



RN 536749-45-8 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(3,4-dichlorophenyl)- (CA INDEX NAME)



RN 536749-48-1 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536749-49-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 536749-52-7 HCPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-fluoro-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536749-53-8 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536749-54-9 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[[[4-chlorophenyl]amino]carbonyl]-5-[[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 536749-55-0 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[(4-chlorophenyl)amino]carbonyl]-5-[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)




RN 536749-56-1 HCAPLUS


CN 3-Pyrrolidinecarboxylic acid, 1-[(4-chlorophenyl)amino]carbonyl]-5-[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 536749-57-2 HCAPLUS  
 CN 1,2,4-Pyrrolidinetricarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 536749-58-3 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-cyano-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 536749-59-4 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-(2H-tetrazol-5-yl)- (CA INDEX NAME)




RN 536749-60-7 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, 4-(aminomethyl)-N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 536749-61-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-[(methylamino)methyl]- (CA INDEX NAME)




RN 536749-62-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[(dimethylamino)methyl]-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 536749-63-0 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, 4-acetyl-N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



IT 536749-64-1P, Pyrrolidine-1,2,4-tricarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 4-methylamide 536749-65-2P,  
 Pyrrolidine-1,2,4-tricarboxylic acid 1-[(4-chlorophenyl)amide]  
 4-dimethylamide 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide]  
 536749-66-3P, 4-Trifluoromethylpyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-67-4P,  
 4-Methylpyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-68-5P,  
 4-Isopropoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-69-6P,  
 4-Fluoropyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-70-9P,  
 4,4-Difluoropyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]

2-[ [2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-71-0P,  
 1-[4-[ [1-[ (4-Chlorophenyl) carbamoyl]-4-methoxypyrrolidine-2-carbonyl] amino] phenyl] pyrrolidine-2-carboxylic acid 536749-72-1P  
 , 1-[4-[ [1-[ (4-Chlorophenyl) carbamoyl]-4-hydroxypyrrolidine-2-carbonyl] amino] phenyl] pyrrolidine-2-carboxylic acid 536749-88-9P  
 , 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[ (4-chlorophenyl) amide]  
 2-[ [2-fluoro-4-(2-hydroxymethyl-5-oxopyrrolidin-1-yl)phenyl]amide]  
 536749-89-0P, 1-[4-[ [1-[ (4-Chlorophenyl) carbamoyl]-4-methoxypyrrolidine-2-carbonyl] amino]-3-fluorophenyl]-5-oxopyrrolidine-2-carboxylic acid 536749-90-3P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[ (4-chlorophenyl) amide]  
 2-[ [4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-fluorophenyl]amide]  
 536749-91-4P, [1-[4-[ [1-[ (4-Chlorophenyl) carbamoyl]-4-methoxypyrrolidine-2-carbonyl] amino]-3-fluorophenyl]-2,5-dioxoimidazolidin-4-yl] acetic acid 536749-92-5P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[ (4-chlorophenyl) amide]  
 2-[ [4-(5,5-dimethyl-2,4-dioxooxazolidin-3-yl)-2-fluorophenyl]amide]  
 536749-93-6P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl) amide] 2-[ [4-(2,5-dioxopyrrolidin-1-yl)-2-fluorophenyl]amide] 536749-94-7P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[ (4-chlorophenyl) amide]  
 2-[ [2-fluoro-4-(2-oxooxazolidin-3-yl)phenyl]amide] 536749-95-8P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[ (4-chlorophenyl) amide]  
 2-[ [4-(2,5-dioxooxazolidin-3-yl)-2-fluorophenyl]amide]  
 536749-96-9P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl) amide] 2-[ [2-fluoro-4-(2-oxoimidazolidin-1-yl)phenyl]amide] 536749-97-0P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[ (4-chlorophenyl) amide]  
 2-[ [4-(2,5-dioxoimidazolidin-1-yl)-2-fluorophenyl]amide]  
 536749-98-1P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl) amide] 2-[ [2-fluoro-4-(3-methyl-2,5-dioxoimidazolidin-1-yl)phenyl]amide] 536749-99-2P,  
 3-[4-[ [1-[ (4-Chlorophenyl) carbamoyl]-4-methoxypyrrolidine-2-carbonyl] amino]-3-fluorophenyl]-2-oxoimidazolidine-4-carboxylic acid 536750-00-2P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl) amide] 2-[ [2-fluoro-4-(2,4,5-trioxoimidazolidin-1-yl)phenyl]amide] 536750-01-3P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[ (4-chlorophenyl) amide]  
 2-[ [4-(2,5-dioxo-2,5-dihydropyrrol-1-yl)-2-fluorophenyl]amide]  
 536750-02-4P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [4-(2-aminomethyl-5-oxopyrrolidin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl) amide] 536750-03-5P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [4-(2-carbamoyl-5-oxopyrrolidin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl) amide] 536750-04-6P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [4-[2,2-bis(hydroxymethyl)-5-oxopyrrolidin-1-yl]-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl) amide] 536750-05-7P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[ (4-chlorophenyl) amide]  
 2-[ [4-(3,3-dimethyl-2,5-dioxopyrrolidin-1-yl)-2-fluorophenyl]amide]  
 536750-06-8P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl) amide] 2-[ [2-fluoro-4-(3,3,4-trimethyl-2,5-dioxopyrrolidin-1-yl)phenyl]amide] 536750-07-9P,  
 1-[4-[ [1-[ (4-Chlorophenyl) carbamoyl]-4-methoxypyrrolidine-2-carbonyl] amino]-3-fluorophenyl]-5-oxopyrrolidine-2,2-dicarboxylic acid 536750-08-0P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl) amide] 2-[ [2-fluoro-4-(2-methyl-5-oxopyrrolidin-1-

yl)phenyl]amide] 536750-09-1P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[2-fluoro-4-(2-methyl-6-oxopiperidin-1-yl)phenyl]amide]  
 536750-10-4P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[2-fluoro-4-(3-hydroxy-2-oxopiperidin-1-  
 yl)phenyl]amide] 536750-11-5P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[2-fluoro-4-(5-methyl-2,6-dioxotetrahydropyrimidin-1-yl)phenyl]amide]  
 536750-12-6P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[2-fluoro-4-(2-oxotetrahydropyrimidin-1-  
 yl)phenyl]amide] 536750-13-7P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[2-fluoro-4-(3-methyl-2-oxo-2H-pyridin-1-yl)phenyl]amide]  
 536750-14-8P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[4-(2,5-dioxopiperazin-1-yl)-2-  
 fluorophenyl]amide] 536750-15-9P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[2-fluoro-4-(3-hydroxy-2-oxo-2H-pyridin-1-yl)phenyl]amide]  
 536750-16-0P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin-1-  
 yl)phenyl]amide] 536750-17-1P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[2-fluoro-4-(6-methyl-2-oxo-4-trifluoromethyl-2H-pyridin-1-  
 yl)phenyl]amide] 536750-18-2P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[4-(2,6-dioxopiperidin-1-yl)-2-fluorophenyl]amide] 536750-19-3P  
 , 1-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-  
 carbonyl]amino]-3-fluorophenyl]-2-oxopiperidine-3-carboxylic acid  
 536750-20-6P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[4-(5,5-dihydroxy-2,4,6-  
 trioxotetrahydropyrimidin-1-yl)-2-fluorophenyl]amide] 536750-21-7P  
 , 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[2-fluoro-4-(2,4,6-trioxotetrahydropyrimidin-1-yl)phenyl]amide]  
 536750-22-8P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[4-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)-2-  
 fluorophenyl]amide] 536750-23-9P,  
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]  
 2-[2-fluoro-4-(2-hydroxy-4-oxoazetidin-1-yl)phenyl]amide]  
 536750-24-0P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[4-(acetyl methylamino)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide]  
 536750-25-1P, 4-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-  
 methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-1H-pyrrole-3-  
 carboxylic acid 536750-26-2P,  
 2-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-  
 carbonyl]amino)-3-fluorophenyl]-2H-pyrazole-3-carboxylic acid  
 536750-27-3P, 1-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-  
 methoxypyrrolidine-2-carbonyl]amino)-3-fluorophenyl]-1H-imidazole-2-  
 carboxylic acid 536750-28-4P,  
 1-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-  
 carbonyl]amino)-3-fluorophenyl]-1H-pyrrole-2-carboxylic acid  
 536750-29-5P, 3-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-  
 methoxypyrrolidine-2-carbonyl]amino)-3-fluorophenyl]-1H-pyrrole-2-  
 carboxylic acid 536750-30-8P,  
 3-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-  
 carbonyl]amino)-3-fluorophenyl]furan-2-carboxylic acid  
 536750-31-9P, 3-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-  
 methoxypyrrolidine-2-carbonyl]amino)-3-fluorophenyl]thiophene-2-carboxylic

acid 536750-32-0P, 4-[4-[(1-(4-Chlorophenyl)carbamoyl)-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]furan-3-carboxylic acid 536750-33-1P, 4-[4-[(1-(4-Chlorophenyl)carbamoyl)-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]thiophene-3-carboxylic acid 536750-42-2P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(5'-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536750-43-3P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5'-difluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536750-44-4P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(5'-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536750-45-5P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5'-difluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536750-47-7P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5'-difluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536750-48-8P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5'-difluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536750-51-3P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(2,3-dimethyl-5-oxo-2,5-dihydropyrazol-1-yl)phenyl]amide] 536750-55-7P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-methyl-5-oxo-5H-[1,2,4]triazin-4-yl)phenyl]amide] 536750-57-9P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(3-chloro-5-methyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide] 536750-58-0P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(3-methyl-5-oxo-4,5-dihydropyrazol-1-yl)phenyl]amide] 536750-59-1P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 2-[[4-(5-chloro-3-methyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide] 536750-60-4P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(3,5-dimethoxy-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536750-61-5P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methoxy-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536750-62-6P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-3-(pyrrol-1-yl)-2H-pyridin-1-yl)phenyl]amide] 536750-63-7P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-3-phenyl-2H-pyridin-1-yl)phenyl]amide] 536750-65-9P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-2-oxopyrrolidin-1-yl)phenyl]amide] 536750-66-0P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-2-oxoimidazolidin-1-yl)phenyl]amide] 536750-67-1P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(3,5-dimethyl-2-oxoimidazolidin-1-yl)-2-fluorophenyl]amide] 536750-68-2P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3,5,5-trimethyl-2-

oxoimidazolidin-1-yl)phenyl]amide] 536750-69-3P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-isopropyl-5,5-dimethyl-2-  
 oxoimidazolidin-1-yl)phenyl]amide] 536750-70-6P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methyl-2-oxoimidazolidin-1-  
 yl)phenyl]amide] 536750-71-7P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(5,5-dimethyl-2-oxoimidazolidin-1-yl)-2-  
 fluorophenyl]amide] 536750-72-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(3,4-dimethyl-2-oxo-2H-pyridin-1-yl)-2-  
 fluorophenyl]amide] 536750-73-9P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(4-chloro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536750-83-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-quinolin-1-  
 yl)phenyl]amide] 536750-84-2P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-oxo-3H-isoquinolin-2-  
 yl)phenyl]amide] 536750-85-3P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(1-oxo-1H-isoquinolin-2-  
 yl)phenyl]amide] 536750-86-4P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-oxo-5H-[1,2,4]triazin-4-  
 yl)phenyl]amide] 536750-87-5P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-oxo-6H-pyrimidin-1-  
 yl)phenyl]amide] 536750-88-6P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-pyrazin-1-  
 yl)phenyl]amide] 536750-89-7P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-pyrimidin-1-  
 yl)phenyl]amide] 536750-90-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-[1,3,5]triazin-1-  
 yl)phenyl]amide] 536750-92-2P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(1-methyl-1H-imidazol-2-  
 yl)phenyl]amide] 536750-93-3P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(1-methyl-1H-pyrrol-2-  
 yl)phenyl]amide] 536750-95-5P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-pyridine-1-  
 carbonyl)phenyl]amide] 536750-96-6P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-3H-imidazol-4-  
 yl)phenyl]amide] 536750-97-7P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-methyl-2H-pyrazol-3-  
 yl)phenyl]amide] 536750-99-9P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-5-oxo-2,5-

dihydropyrazol-1-yl)phenyl]amide] 536751-00-5P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methoxymethyl-3-methylpyrazol-1-yl)phenyl]amide] 536751-01-6P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methoxymethyl-5-methylpyrazol-1-yl)phenyl]amide] 536751-02-7P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-ethyl-3-methylpyrazol-1-yl)phenyl]amide] 536751-03-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-isobutyl-3-methylpyrazol-1-yl)phenyl]amide] 536751-04-9P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-isopropylpyrazol-1-yl)phenyl]amide] 536751-05-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-ethylpyrazol-1-yl)phenyl]amide] 536751-06-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-isobutylpyrazol-1-yl)phenyl]amide] 536751-07-2P,  
 (2R, 4R)-2-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2H-pyrazole-3-carboxylic acid methyl ester 536751-08-3P, (2R, 4R)-2-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino)-3-fluorophenyl]-2H-pyrazole-3-carboxylic acid 536751-09-4P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methoxymethylpyrazol-1-yl)phenyl]amide] 536751-10-7P,  
 (2R, 4R)-5-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino)-3-fluorophenyl]oxazole-4-carboxylic acid ethyl ester 536751-11-8P, (2R, 4R)-5-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-hydroxypyrrolidine-2-carbonyl]amino)-3-fluorophenyl]oxazole-4-carboxylic acid ethyl ester 536751-12-9P,  
 (2R, 4R)-5-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino)-3-fluorophenyl]oxazole-4-carboxylic acid 536751-13-0P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-methoxymethyloxazol-5-yl)phenyl]amide] 536751-14-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(4-ethyloxazol-5-yl)-2-fluorophenyl]amide] 536751-15-2P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-isopropyloxazol-5-yl)phenyl]amide] 536751-22-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-methylisoxazol-3-yl)phenyl]amide] 536751-23-2P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(4-methylisoxazol-3-yl)phenyl]amide] 536751-24-3P, (2R, 4R)-3-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino)-3-fluorophenyl]isoazazole-4-carboxylic acid methyl ester 536751-25-4P,  
 (2R, 4R)-3-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino)-3-fluorophenyl]isoazazole-4-carboxylic acid 536751-26-5P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(4-methoxymethylisoxazol-3-

yl)phenyl]amide] 536751-27-6P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-isopropylisoxazol-3-  
 yl)phenyl]amide] 536751-28-7P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-cyclopropylisoxazol-3-  
 yl)phenyl]amide] 536751-29-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(4-cyclopropylisoxazol-3-yl)phenyl]amide]  
 536751-31-2P, (2R, 4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-methyl-4-(2-oxo-2H-pyridin-1-  
 yl)phenyl]amide] 536751-45-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-[(ethylisopropyl)carbamoyl]phenyl]amide]  
 536751-46-9P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-[(ethylisopropyl)carbamoyl]-2-  
 fluorophenyl]amide] 536751-47-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(3-ethylpyrrolidine-1-carbonyl)-2-  
 carbonyl]phenyl]amide] 536751-48-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(3-ethylpyrrolidine-1-carbonyl)-2-  
 fluorophenyl]amide] 536751-49-2P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(3R-aminopyrrolidine-1-carbonyl)phenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536751-50-5P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(3R-aminopyrrolidine-1-carbonyl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536751-51-6P  
 , (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(3S-aminopyrrolidine-1-carbonyl)phenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536751-52-7P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(3S-aminopyrrolidine-1-carbonyl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536751-53-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(3R-methylaminopyrrolidine-1-  
 carbonyl)phenyl]amide] 536751-54-9P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(3R-methylaminopyrrolidine-1-  
 carbonyl)phenyl]amide] 536751-55-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(3S-methylaminopyrrolidine-1-  
 carbonyl)phenyl]amide] 536751-56-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(3S-methylaminopyrrolidine-1-  
 carbonyl)phenyl]amide] 536751-57-2P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(3R-ethylaminopyrrolidine-1-  
 carbonyl)phenyl]amide] 536751-58-3P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(3R-ethylaminopyrrolidine-1-  
 carbonyl)phenyl]amide] 536751-59-4P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(3S-ethylaminopyrrolidine-1-  
 carbonyl)phenyl]amide] 536751-60-7P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid

1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3S-ethylaminopyrrolidine-1-carbonyl)phenyl]amide] 536751-62-9P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[4-(2,5-dihydropyrrole-1-carbonyl)-2-fluorophenyl]amide] 536751-64-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[4-(pyrrole-1-carbonyl)phenyl]amide]  
 536751-65-2P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(pyrrole-1-carbonyl)phenyl]amide]  
 536751-68-5P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-fluoro-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536751-69-6P,  
 (2R, 4R)-1-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl)amino]-3-fluorophenyl]-6-oxo-1,6-dihydropyridine-3-carboxylic acid 536751-70-9P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-hydroxy-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536751-71-0P,  
 (2R, 4R)-1-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl)amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid 536751-72-1P, (2R, 4R)-1-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl)amino]-3-fluorophenyl]-6-oxo-1,6-dihydropyridine-2-carboxylic acid methyl ester 536751-73-2P,  
 (2R, 4R)-[1-[(4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl)amino]phenyl]-2,5-dioxoimidazolidin-4-yl]acetic acid 536751-74-3P, (2R, 4R)-1-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl)amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid methyl ester 536751-75-4P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-3-trifluoromethyl-2H-pyridin-1-yl)phenyl]amide] 536751-76-5P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-hydroxy-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536751-77-6P,  
 (2R, 4R)-1-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl)amino]-3-fluorophenyl]-6-oxo-1,6-dihydropyridine-2-carboxylic acid 536751-78-7P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-5-trifluoromethyl-2H-pyridin-1-yl)phenyl]amide] 536751-79-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[4-(6-cyclopropyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536751-80-1P,  
 (2R, 4R)-1-[4-[(1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl)amino]-3-fluorophenyl]-6-oxo-1,6-dihydropyridine-3-carboxylic acid ethyl ester 536751-81-2P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[4-(3,3-dimethyl-2-oxoazetidin-1-yl)phenyl]amide] 536751-82-3P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(7-oxo-7H-thieno[2,3-c]pyridin-6-yl)phenyl]amide] 536751-83-4P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-1-azaspiro[4.5]dec-1-yl)phenyl]amide] 536751-84-5P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(3-benzoyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[(4-chlorophenyl)amide] 536751-85-6P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid

2-[ [4-(3-acetylsulfamoyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536751-86-7P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-oxothiazolidin-3-  
 yl)phenyl]amide] 536751-87-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(3-methyl-2-oxopiperidin-1-  
 yl)phenyl]amide] 536751-88-9P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-oxo-3-sulfamoyl-2H-pyridin-1-  
 yl)phenyl]amide] 536751-89-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(2,5-dioxo-2,5-dihydropyrrol-1-  
 yl)phenyl]amide] 536751-90-3P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [4-(3-amino-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536751-91-4P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-oxo-3-phenoxy-2H-pyridin-1-  
 yl)phenyl]amide] 536751-92-5P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(2,2-dimethyl-5-oxopyrrolidin-1-yl)-2-  
 fluorophenyl]amide] 536751-93-6P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(3-nitro-2-oxo-2H-pyridin-1-  
 yl)phenyl]amide] 536751-94-7P,  
 (2R, 4R)-1-[4-[1-[ (4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-  
 carbonyl]amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridine-3-carboxylic  
 acid tert-butyl ester 536751-95-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(2,5-dioxopyrrolidin-1-yl)phenyl]amide]  
 536751-96-9P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [4-(3-benzothiazol-2-yl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536751-97-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [4-(3-amino-4,6-dimethyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536751-98-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(3-diethylaminomethyl-2-oxo-2H-pyridin-1-  
 yl)-2-fluorophenyl]amide] 536751-99-2P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [4-(3-aminomethyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536752-00-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(3-methyl-5-nitro-2-oxo-2H-  
 pyridin-1-yl)phenyl]amide] 536752-01-9P, (2R, 4R)-Acetic acid  
 1-[4-[1-[ (4-chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-  
 carbonyl]amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridin-3-yl ester  
 536752-02-0P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-[3-[(cyclopentanecarbonyl)amino]-2-oxo-2H-  
 pyridin-1-yl]-2-fluorophenyl]amide] 536752-03-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [4-(5-amino-3-methyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536752-04-2P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-[2-oxo-3-[(pyridin-4-  
 yl)carbamoyl]-2H-pyridin-1-yl]phenyl]amide]


10594024

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)


RN 536749-64-1 HCPLUS

CN 1,2,4-Pyrrolidinetricarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-N4-methyl- (CA INDEX NAME)



RN 536749-65-2 HCPLUS

CN 1,2,4-Pyrrolidinetricarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-N4,N4-dimethyl- (CA INDEX NAME)




RN 536749-66-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-


10594024

piperidinyl)phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 536749-67-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methyl- (CA INDEX NAME)




RN 536749-68-5 HCPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-(1-methylethoxy)- (CA INDEX NAME)



RN 536749-69-6 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-fluoro-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 536749-70-9 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4,4-difluoro-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 536749-71-0 HCAPLUS

CN Proline, 1-[4-[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 536749-72-1 HCAPLUS

CN Proline, 1-[4-[[1-[(4-chlorophenyl)amino]carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 536749-88-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[2-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]phenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-89-0 HCAPLUS

CN Proline, 1-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-5-oxo- (CA INDEX NAME)




RN 536749-90-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-91-4 HCPLUS

CN 4-Imidazolidineacetic acid, 1-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-2,5-dioxo- (CA INDEX NAME)




RN 536749-92-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(5,5-dimethyl-2,4-dioxo-3-oxazolidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-93-6 HCPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dioxo-1-pyrrolidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)



RN 536749-94-7 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-3-methoxy-3-oxazolidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-95-8 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dioxo-3-oxazolidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-96-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-imidazolidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-97-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dioxo-1-imidazolidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-98-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-2,5-dioxo-1-imidazolinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-99-2 HCAPLUS

CN 4-Imidazolidinecarboxylic acid, 3-[4-[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-2-oxo- (CA INDEX NAME)




RN 536750-00-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2,4,5-trioxo-1-imidazolidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-01-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-02-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[2-(aminomethyl)-5-oxo-1-pyrrolidinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy- (CA INDEX NAME)




RN 536750-03-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[2-(aminocarbonyl)-5-oxo-1-pyrrolidinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy- (CA INDEX NAME)




RN 536750-04-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[2,2-bis(hydroxymethyl)-5-oxo-1-pyrrolidinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy- (CA INDEX NAME)




RN 536750-05-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,3-dimethyl-2,5-dioxo-1-pyrrolidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-06-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3,3,4-trimethyl-2,5-dioxo-1-pyrrolidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-07-9 HCAPLUS

CN 2,2-Pyrrolidinedicarboxylic acid, 1-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-5-oxo- (CA INDEX NAME)




RN 536750-08-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-methyl-5-oxo-1-pyrrolidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-09-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-methyl-6-oxo-1-piperidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-10-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-hydroxy-2-oxo-1-piperidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-11-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(tetrahydro-5-methyl-2,6-dioxo-1(2H)-pyrimidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-12-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-13-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-14-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dioxo-1-piperazinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-15-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-hydroxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-16-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methoxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-17-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[6-methyl-2-oxo-4-(trifluoromethyl)-1(2H)-pyridinyl]phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-18-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,6-dioxo-1-piperidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-19-3 HCAPLUS

CN 3-Piperidinecarboxylic acid, 1-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-2-oxo- (CA INDEX NAME)




RN 536750-20-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(tetrahydro-5,5-dihydroxy-2,4,6-trioxa-1(2H)-pyrimidinyl)phenyl]-4-methoxy-  
(CA INDEX NAME)


RN 536750-21-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(tetrahydro-2,4,6-trioxa-1(2H)-pyrimidinyl)phenyl]-4-methoxy- (CA INDEX  
NAME)




RN 536750-22-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-23-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-hydroxy-4-oxo-1-azetidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-24-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[(2-oxopropyl)amino]phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-25-1 HCAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 4-[4-[[1-[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)



RN 536750-26-2 HCAPLUS  
 CN 1H-Pyrazole-5-carboxylic acid, 1-[4-[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)




RN 536750-27-3 HCAPLUS  
 CN 1H-Imidazole-2-carboxylic acid, 1-[4-[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)




RN 536750-28-4 HCPLUS

CN 1H-Pyrrole-2-carboxylic acid, 1-[4-[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)




RN 536750-29-5 HCPLUS

CN 1H-Pyrrole-2-carboxylic acid, 3-[4-[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)




RN 536750-30-8 HCAPLUS

CN 2-Furancarboxylic acid, 3-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl- (CA INDEX NAME)




RN 536750-31-9 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl- (CA INDEX NAME)




RN 536750-32-0 HCAPLUS

CN 3-Furancarboxylic acid, 4-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl- (CA INDEX NAME)




RN 536750-33-1 HCAPLUS

CN 3-Thiophencarboxylic acid, 4-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl- (CA INDEX NAME)




RN 536750-42-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-5'-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-methoxy- (CA INDEX NAME)




RN 536750-43-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3,5-difluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-methoxy- (CA INDEX NAME)




RN 536750-44-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[5'-fluoro-2'-(methyloxymethylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methoxy- (CA INDEX NAME)




RN 536750-45-5 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-difluoro-2-(methyloxymethylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methoxy- (CA INDEX NAME)




RN 536750-47-7 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3,5'-difluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)




RN 536750-48-8 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3,5'-difluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)



RN 536750-51-3 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-55-7 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-oxo-1(6H)-pyridazinyl)phenyl]-4-methoxy- (CA INDEX NAME)



RN 536750-56-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-methyl-5-oxo-1,2,4-triazin-4(5H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-57-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(3-chloro-5-methyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-58-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-59-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-chloro-3-methyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536750-60-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,5-dimethoxy-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-61-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-methoxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-62-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[2-oxo-3-(1H-pyrol-1-yl)-1(2H)-pyridinyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-63-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-3-phenyl-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-65-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1-pyrrolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536750-66-0 HCPLUS

10594024

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1-imidazolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-67-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,5-dimethyl-2-oxo-1-imidazolidinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-68-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3,5,5-trimethyl-2-oxo-1-imidazolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-69-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[5,5-dimethyl-3-(1-methylethyl)-2-oxo-1-imidazolidinyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)-(CA INDEX NAME)


Absolute stereochemistry.



RN 536750-70-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-methyl-2-oxo-1-imidazolidinyl)phenyl]-4-methoxy-, (2R,4R)-(CA INDEX NAME)

Absolute stereochemistry.




RN 536750-71-7 HCPLUS

10594024

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(5,5-dimethyl-2-oxo-1-imidazolidinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-72-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,4-dimethyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-73-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4-chloro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-83-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-quinolinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-84-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-2(3H)-isoquinolinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-85-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-oxo-2(1H)-isoquinolinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-86-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-oxo-1,2,4-triazin-4(5H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-87-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-oxo-1(6H)-pyrimidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-88-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyrazinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-89-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyrimidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-90-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1,3,5-triazin-1(2H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-92-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-methyl-1H-imidazol-2-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-93-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-methyl-1H-pyrrrol-2-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536750-95-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[(2-oxo-1(2H)-pyridinyl)carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

10594024


Absolute stereochemistry.



RN 536750-96-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-methyl-1H-imidazol-5-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-97-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-99-9 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-00-5 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[5-(methoxymethyl)-3-methyl-1H-pyrazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536751-01-6 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[3-(methoxymethyl)-5-methyl-1H-pyrazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-02-7 HCAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(5-ethyl-3-methyl-

10594024

1H-pyrazol-1-yl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-03-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[3-methyl-5-(2-methylpropyl)-1H-pyrazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-04-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[5-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-05-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(5-ethyl-1H-pyrazol-1-yl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-06-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[5-(2-methylpropyl)-1H-pyrazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-07-2 HCPLUS

10594024

CN 1H-Pyrazole-5-carboxylic acid, 1-[4-[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-08-3 HCPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[4-[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-09-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[5-(methoxymethyl)-1H-pyrazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-10-7 HCPLUS

CN 4-Oxazolecarboxylic acid, 5-[4-[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-11-8 HCPLUS

CN 4-Oxazolecarboxylic acid, 5-[4-[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536751-12-9 HCAPLUS

CN 4-Oxazolecarboxylic acid, 5-[4-[[[(2R,4R)-1-[[[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-13-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[4-(methoxymethyl)-5-oxazolyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-14-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4-ethyl-5-oxazolyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-15-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[4-(1-methylethyl)-5-oxazolyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-22-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-methyl-3-isoxazolyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-23-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(4-methyl-3-isoxazolyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

10594024


Absolute stereochemistry.



RN 536751-24-3 HCAPLUS

CN 4-Isoxazolecarboxylic acid, 3-[4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-25-4 HCAPLUS

CN 4-Isoxazolecarboxylic acid, 3-[4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-26-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-[4-(methoxymethyl)-3-isoxazolyl]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-27-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[4-(1-methylethyl)-3-isoxazolyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-28-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4-cyclopropyl-3-isoxazolyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

10594024


Absolute stereochemistry.



RN 536751-29-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4-cyclopropyl-3-isoxazolyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-31-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-methyl-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536751-45-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[ethyl(1-methylethyl)amino]carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-46-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[ethyl(1-methylethyl)amino]carbonyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-47-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(3-ethyl-1-pyrrolidinyl)carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-48-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(3-ethyl-1-pyrrolidinyl)carbonyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-49-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(3R)-3-amino-1-pyrrolidinyl]carbonyl]phenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-50-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(3R)-3-amino-1-pyrrolidinyl]carbonyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-,

10594024

(2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-51-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(3S)-3-amino-1-(4-chlorophenyl)-4-methoxy-1-pyrrolidinyl]carbonyl]phenyl]-N1-(4-fluorophenyl)-4-methoxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-52-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(3S)-3-amino-1-(4-chlorophenyl)-4-methoxy-1-pyrrolidinyl]carbonyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-53-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(3R)-3-(methylamino)-1-pyrrolidinyl]carbonyl]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-54-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[(3R)-3-(methylamino)-1-pyrrolidinyl]carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-55-0 HCPLUS

10594024

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-[(3S)-3-(methylamino)-1-pyrrolidinyl]carbonyl]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-56-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[(3S)-3-(methylamino)-1-pyrrolidinyl]carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-57-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536751-58-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]carbonyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 536751-59-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(3S)-3-(ethylamino)-1-pyrrolidinyl]carbonyl]phenyl]-4-methoxy-, (2R,4R)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 536751-60-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(3S)-3-(ethylamino)-1-pyrrolidinyl]carbonyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 536751-62-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2,5-dihydro-1H-pyrrol-1-yl)carbonyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-64-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(1H-pyrrol-1-ylcarbonyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-65-2 HCPLUS

10594024

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1H-pyrrol-1-ylcarbonyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-68-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-fluoro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-69-6 HCPLUS

CN 3-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-70-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-hydroxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-71-0 HCPLUS

CN 3-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-72-1 HCPLUS

10594024

CN 2-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,6-dihydro-6-oxo-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-73-2 HCAPLUS

CN 4-Imidazolidineacetic acid, 1-[4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]phenyl]-2,5-dioxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-74-3 HCAPLUS

CN 3-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,2-dihydro-2-oxo-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-75-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[2-oxo-3-(trifluoromethyl)-1(2H)-pyridinyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-76-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-hydroxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-77-6 HCAPLUS

CN 2-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-78-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-79-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(6-cyclopropyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-80-1 HCPLUS

CN 3-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[[[4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,6-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-81-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,3-dimethyl-2-oxo-1-azetidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-82-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(7-oxothieno[2,3-c]pyridin-6(7H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-83-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-azaspiro[4.5]dec-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-84-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(3-benzoyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-85-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[3-[(acetylamino)sulfonyl]-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-86-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-3-thiazolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-87-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1-piperidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-88-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[3-(aminosulfonyl)-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-89-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-90-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(3-amino-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-91-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-3-phenoxy-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-92-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,2-dimethyl-5-oxo-1-pyrrolidinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-93-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-nitro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536751-94-7 HCAPLUS

CN 3-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,2-dihydro-2-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-95-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dioxo-1-pyrrolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-96-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[3-(2-benzothiazolyl)-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-97-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(3-amino-4,6-dimethyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-98-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[3-[(diethylamino)methyl]-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-99-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[3-(aminomethyl)-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-00-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-5-nitro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-01-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[3-(acetyloxy)-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-02-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[3-[(cyclopentylcarbonyl)amino]-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536752-03-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-amino-3-methyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-04-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[2-oxo-3-[(4-pyridinylamino)carbonyl]-1(2H)-pyridinyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 536752-05-3P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid

1-[(4-chlorophenyl)amide] 2-[[4-(3,5-dichloro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536752-06-4P,

(2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid

2-[[4-(3-amino-5-bromo-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]

1-[(4-chlorophenyl)amide] 536752-07-5P,

(2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid

1-[(4-chlorophenyl)amide] 2-[[4-(3-cyano-2-oxo-2H-pyridin-1-yl)-2-

fluorophenyl]amide] 536752-08-6P,

(2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid

1-[(4-chlorophenyl)amide] 2-[[4-(3-cyano-2-oxo-5-phenyl-2H-pyridin-1-yl)-2-

fluorophenyl]amide] 536752-09-7P,

(2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(3-ethyl-6-methyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536752-10-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[4-(3-cyano-4-dimethylamino-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536752-11-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-methyl-3-nitro-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536752-12-2P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-nitro-2-oxo-3-trifluoromethyl-2H-pyridin-1-yl)phenyl]amide] 536752-13-3P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(5-amino-6-oxo-6H-[3,4']bipyridinyl-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536752-14-4P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(5-chloro-3-nitro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536752-15-5P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(3-carbamoyl-2-oxo-5-trifluoromethyl-2H-pyridin-1-yl)-2-fluorophenyl]amide] 1-[ (4-chlorophenyl)amide] 536752-16-6P,  
 (2R, 4R)-5-Bromo-1-[4-[(1-[(4-chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid isobutyl ester 536752-17-7P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(3-chloro-2-oxo-5-trifluoromethyl-2H-pyridin-1-yl)-2-fluorophenyl]amide] 1-[ (4-chlorophenyl)amide] 536752-18-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(3-bromo-5-chloro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536752-19-9P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(5-bromo-3-nitro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536752-20-2P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-nitro-2-oxo-5-trifluoromethyl-2H-pyridin-1-yl)phenyl]amide] 536752-21-3P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methyl-3-nitro-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536752-22-4P,  
 (2R, 4R)-5-Chloro-1-[4-[(1-[(4-chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid methyl ester 536752-23-5P,  
 (2R, 4R)-5-Chloro-1-[4-[(1-[(4-chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid 536752-24-6P, (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 2-[[4-(4-benzyloxy-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536752-25-7P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(4-amino-5-fluoro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536752-26-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-methyl-3-oxo-3H-isquinolin-2-yl)phenyl]amide] 536752-27-9P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-methyl-5-nitro-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536752-28-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid


2-[ [4-(5-acetylamino-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536752-29-1P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [4-(4-amino-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536752-30-4P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(6-oxo-6H-[3,4']bipyridinyl-1-  
 yl)phenyl]amide] 536752-31-5P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [4-(4-bromo-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536752-32-6P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(4-oxo-4H-furo[3,2-c]pyridin-5-  
 yl)phenyl]amide] 536752-33-7P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(1-oxo-1H-[2,6]naphthyridin-2-  
 yl)phenyl]amide] 536752-34-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [4-(5-bromo-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536752-35-9P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(4-oxo-4H-thieno[3,2-c]pyridin-5-  
 yl)phenyl]amide] 536752-36-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(4-oxo-1,4-dihydroimidazo[4,5-  
 c]pyridin-5-yl)phenyl]amide] 536753-22-7P,  
 (2R, 4R)-4-Methoxy-2-methylpyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-oxopiperidin-1-  
 yl)phenyl]amide] 536753-24-9P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(2-dimethylaminomethylimidazol-1-yl)-2-  
 fluorophenyl]amide] 536753-25-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[ [2-chloro-4-(2-oxo-2H-pyridin-1-yl)phenyl]amide]  
 1-[ (4-chlorophenyl)amide] 536753-27-2P,  
 (2R, 4R)-4-Methylpyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-oxo-2H-pyridin-1-  
 yl)phenyl]amide] 536753-28-3P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-methylaminoimidazol-1-  
 yl)phenyl]amide] 536753-31-8P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [4-(2-ethylimidazol-1-yl)-2-  
 fluorophenyl]amide] 536753-33-0P,  
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-isopropylimidazol-1-  
 yl)phenyl]amide] 536753-34-1P,  
 (2R, 4R)-2-Ethyl-4-methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-oxopiperidin-1-  
 yl)phenyl]amide] 536753-35-2P,  
 4-Methoxy-2-methoxymethylpyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-oxopiperidin-1-  
 yl)phenyl]amide] 536753-36-3P,  
 2-Hydroxymethyl-4-methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[ (4-chlorophenyl)amide] 2-[ [2-fluoro-4-(2-oxopiperidin-1-  
 yl)phenyl]amide] 536753-37-4P,  
 [1-[ (4-Chlorophenyl)carbamoyl]-2-[ [2-fluoro-4-(2-oxopiperidin-1-

yl)phenyl]carbamoyl]-4-methoxypyrrolidin-2-yl]acetic acid methyl ester  
 536753-38-5P, [1-[(4-Chlorophenyl)carbamoyl]-2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]carbamoyl]-4-methoxypyrrolidin-2-yl]acetic acid  
 536753-39-6P, 4-Hydroxymethylpyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536753-41-0P,  
 [1-[(4-Chlorophenyl)carbamoyl]-5-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]carbamoyl]pyrrolidin-3-yl]acetic acid 536753-43-2P,  
 [1-[(4-Chlorophenyl)carbamoyl]-5-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]carbamoyl]pyrrolidin-3-yl]acetic acid methyl ester  
 536753-45-4P, (2R,4R)-4-Ethylpyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenyl]amide] 536753-47-6P,  
 (2R,4R)-4-Isopropylpyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenyl]amide] 536753-49-8P,  
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-fluoro-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536753-55-6P,  
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(3-chloro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[(4-chlorophenyl)amide] 536753-57-8P,  
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 2-[[4-(3-bromo-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]  
 1-[(4-chlorophenyl)amide] 536753-61-4P,  
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-iodo-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536753-67-0P,  
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[4-(3-ethyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536753-69-2P,  
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid  
 1-[(4-chlorophenyl)amide] 2-[[2-methyl-4-(2-oxo-2H-pyridin-1-yl)phenyl]amide]  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (drug candidate; preparation of pyrrolidinedicarboxamides and related  
 compds. as inhibitors of factor Xa useful for thrombotic disorders)

RN 536752-05-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,5-dichloro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-06-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(3-amino-5-bromo-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-07-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-cyano-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-08-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-cyano-2-oxo-5-phenyl-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-09-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-ethyl-6-methyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-10-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[3-cyano-4-(dimethylamino)-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-11-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-methyl-3-nitro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-12-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[5-nitro-2-oxo-3-(trifluoromethyl)-1(2H)-pyridinyl]phenyl]-4-methoxy-, (2R,4R)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 536752-13-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-amino-6-oxo[3,4'-bipyridin]-1(6H)-yl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 536752-14-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-chloro-3-nitro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-15-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[3-(aminocarbonyl)-2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-16-6 HCPLUS

CN 3-Pyridinecarboxylic acid, 5-bromo-1-[4-[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,2-dihydro-2-oxo-, 2-methylpropyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-17-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[3-chloro-2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-18-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(3-bromo-5-chloro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-19-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-bromo-3-nitro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-20-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[3-nitro-2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]phenyl]-4-methoxy-, (2R,4R)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 536752-21-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-methyl-3-nitro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 536752-22-4 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-1-[4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,2-dihydro-2-oxo-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-23-5 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-1-[4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-24-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[2-oxo-4-(phenylmethoxy)-1(2H)-pyridinyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-25-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4-amino-5-fluoro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536752-26-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-methyl-3-oxo-2(3H)-isoquinolinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-27-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-methyl-5-nitro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-28-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[5-(acetylamino)-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-29-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4-amino-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-30-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-oxo[3,4'-bipyridin]-1(6H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536752-31-5 HCPLUS

10594024

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4-bromo-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-32-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-oxofuro[3,2-c]pyridin-5(4H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-33-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-oxo-2,6-naphthyridin-2(1H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536752-34-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-bromo-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-35-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-oxothieno[3,2-c]pyridin-5(4H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-36-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,4-dihydro-4-oxo-5H-imidazo[4,5-c]pyridin-5-yl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-22-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methoxy-2-methyl-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-24-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536753-25-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2-chloro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)

10594024


Absolute stereochemistry.



RN 536753-27-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methyl-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-28-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(methylamino)-1H-imidazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536753-31-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-ethyl-1H-

10594024

imidazol-1-yl)-2-fluorophenyl]-4-methoxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-33-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[2-(1-methylethyl)-1H-imidazol-1-yl]phenyl]-4-methoxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-34-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-2-ethyl-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methoxy-, (2R, 4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-35-2 HCPLUS


10594024

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methoxy-2-(methoxymethyl)- (CA INDEX NAME)




RN 536753-36-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-2-(hydroxymethyl)-4-methoxy- (CA INDEX NAME)




RN 536753-37-4 HCPLUS

CN 2-Pyrrolidineacetic acid, 1-[(4-chlorophenyl)amino]carbonyl]-2-[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]-4-methoxy-, methyl ester (CA INDEX NAME)




RN 536753-38-5 HCAPLUS

CN Benzoic acid, 2-(acetyloxy)-, 1-[[[(4-chlorophenyl)amino]carbonyl]-2-[[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl ester (CA INDEX NAME)




RN 536753-39-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-(hydroxymethyl)- (CA INDEX NAME)




RN 536753-41-0 HCAPLUS

CN Benzoic acid, 2-(acetyloxy)-, 1-[[[4-chlorophenyl)amino]carbonyl]-5-[[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]-3-pyrrolidinyl ester  
(CA INDEX NAME)

RN 536753-43-2 HCAPLUS


CN 3-Pyrrolidineacetic acid, 1-[[[4-chlorophenyl)amino]carbonyl]-5-[[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)



RN 536753-45-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-47-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-(1-methylethyl)-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536753-49-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-fluoro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-55-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(3-chloro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-57-8 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(3-bromo-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-61-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-iodo-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-67-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-ethyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-69-2 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[2-methyl-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 536747-74-7, (2R,4S)-Toluene-4-sulfonic acid

1-[(4-chlorophenyl)carbamoyl]-5-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)carbamoyl]pyrrolidin-3-yl ester


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)

RN 536747-74-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-[(4-methylphenyl)sulfonyloxy]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 536746-28-8P, (R)-Pyrrolidine-1,2-dicarboxylic acid

2-[(2'-tert-butylsulfonyl)-3-fluorobiphenyl-4-yl]amide]

1-[(4-chlorophenyl)amide] 536746-32-4P,


Pyrrolidine-1,2-dicarboxylic acid 2-[(2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide] 1-[(4-chlorophenyl)amide] 536747-57-6P  
, (2R,4R)-4-Hydroxypyrrrolidine-1,2-dicarboxylic acid  
2-[(2'-tert-butylsulfamoyl-3,5'-difluorobiphenyl-4-yl)amide]  
1-[(4-chlorophenyl)amide] 536747-71-4P,  
(2R,4R)-Toluene-4-sulfonic acid 1-[(4-chlorophenyl)carbamoyl]-5-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)carbamoyl]pyrrolidin-3-yl ester  
536747-72-5P, (2R,4S)-4-Azidopyrrolidine-1,2-dicarboxylic acid  
1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-02-4P, (2R,4R)-4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrrolidine-2-carbonyl]amino]benzoic acid  
methyl ester 536748-03-5P,  
(2R,4R)-4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrrolidine-2-carbonyl]amino]benzoic acid  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)

RN 536746-28-8 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2'-[(1,1-dimethylethyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536746-32-4 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2'-(1,1-dimethylethyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536747-57-6 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2'-(1,1-dimethylethyl)amino]sulfonyl]-3,5'-difluoro[1,1'-biphenyl]-4-yl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-71-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-[(4-methylphenyl)sulfonyloxy]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-72-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-azido-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-02-4 HCPLUS

CN Benzoic acid, 4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-03-5 HCAPLUS

CN Benzoic acid, 4-[[[2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:352811 HCAPLUS

DOCUMENT NUMBER: 129:40984

ORIGINAL REFERENCE NO.: 129:8615a,8618a

TITLE: Preparation of acylamino-substituted acylanilide derivatives as antiandrogenic agents

INVENTOR(S): Taniguchi, Nobuaki; Okada, Minoru; Kaku, Hidetaka; Shimada, Itsuro; Nozawa, Eisuke; Koutoku, Hiroshi; et al.

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9822432	A1	19980528	WO 1997-JP4174	19971117 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9749664	A	19980610	AU 1997-49664	19971117 <--
PRIORITY APPLN. INFO.:			JP 1996-306192	A 19961118
			WO 1997-JP4174	W 19971117

OTHER SOURCE(S): MARPAT 129:40984  
GI




AB The title compds. [I; R1, R2 = halo, cyano, haloalkyl, NO<sub>2</sub>, etc.; R3 = H, lower alkyl; R4-R7 = H, (un)substituted lower alkyl, aralkyl, etc.; R8 = H, OH, lower alkoxy or alkyl, etc.; n = 0, 1; A1, A2 = lower alkylene; Z = acyl; X1 = O, S] are prepared I have an antiandrogenic activity and are useful as a prophylactic or therapeutic agent for prostatic cancer, prostatic hypertrophy, defemination, hypertrichosis, bald head, acne, seborrhea and the like in which androgen is involved as an exacerbating factor. Thus, p-FC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>NHC<sub>2</sub>H<sub>5</sub>CO<sub>2</sub>H was treated with (COCl)<sub>2</sub> and then reacted with 4-amino-2-trifluoromethylbenzonitrile to give I (R1 = CF<sub>3</sub>, R2 = cyano, R3 = R5 = R8 = H, n = 0, Z = p-FC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>, X1 = O), which showed IC<sub>50</sub> of 0.56 nM antagonist activity when tested with androgen receptor.

IT 208121-51-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of acylamino-substituted acylanilide derivs. as antiandrogenic agents)

RN 208121-51-1 HCPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 18 ibib abs tot

L8 ANSWER 1 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:559353 HCPLUS

DOCUMENT NUMBER: 149:215504

TITLE: Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis

AUTHOR(S): Karnicki, Krzysztof; Leadley, Robert J., Jr.; Baxi, Sangita; Peterson, Thomas; Wysokinski, Waldemar; McBane, Robert D., II

CORPORATE SOURCE: Section of Hematology Research, Mayo Clinic, Rochester, MN, USA

SOURCE: Thrombosis and Haemostasis (2008), 99(4), 759-766  
CODEN: THHADQ; ISSN: 0340-6245

PUBLISHER: Schattauer GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The objective of this study was to determine if orally-administered PD0348292, a direct specific factor Xa inhibitor, inhibits thrombosis following porcine carotid arterial injury comparably to aspirin or clopidogrel alone or in combination. We further sought to determine whether the antithrombotic efficacy *in vivo* could be predicted using an ex-vivo perfusion chamber. Oral treatments included: PD0348292 (0.4, 0.9, or 4.3 mg/kg); PD0348292 (0.4 mg/kg) plus aspirin (325 mg); aspirin; clopidogrel (75 mg); aspirin plus clopidogrel; or vehicle (*n* = 6-10/group). Aspirin and clopidogrel were administered 27 and 4 h pre-injury and PD0348292 or vehicle was administered 4 h pre-injury. Both carotid arteries were crush-injured, and thrombus was measured by detection of <sup>111</sup>In-platelets over 30 min. Prior to injury, the antithrombotic efficacy was assessed by ex-vivo perfusion chamber platelet deposition. PD0348292 produced dose-dependent prothrombin time (0.9- to 2.9-fold) and aPTT (1.4- to 2.5-fold) prolongations. Bleeding times were significantly prolonged in each active drug group compared to vehicle, but were not significantly different between drug groups. PD0348292 significantly inhibited arterial platelet deposition ( $\times 10^6/cm^2$ ) at 4.3( $549 \pm 1,066$ ), 0.9 (399  $\pm$  162) and 0.4

mg/kg (531 ± 470) compared to vehicle (2,242 ± 1,443). Aspirin (992 ± 973), clopidogrel (537 ± 483), clopidogrel plus aspirin (228 ± 66) or PD0348292 plus aspirin (558 ± 317) also significantly inhibited platelet deposition, although these values were not significantly different than with any dose of PD348292. Perfusion chamber platelet deposition correlated significantly with in-vivo anti-thrombotic response. In conclusion, PD0348292 inhibited arterial thrombosis comparable to aspirin plus clopidogrel. Perfusion chamber methodol. may be useful in predicting in-vivo antithrombotic efficacy.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2008:559338 HCPLUS  
 DOCUMENT NUMBER: 149:172384  
 TITLE: Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor

AUTHOR(S): Andreotti, Felicita; Santucci, Eleonora  
 CORPORATE SOURCE: Department of Cardiovascular Medicine, University Hospital "A. Gemelli", Rome, Italy  
 SOURCE: Thrombosis and Haemostasis (2008), 99(4), 651-652  
 CODEN: THHADQ; ISSN: 0340-6245

PUBLISHER: Schattauer GmbH  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English

AB A review. Role of coagulation in pathogenesis of arterial thrombosis is reviewed here. Mechanisms of actions of a variety of anticoagulants such as heparins, coumarins and fondaparinux are described. Mechanism of action of a new anticoagulant PD0348292 is described in detail.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2008:227623 HCPLUS  
 DOCUMENT NUMBER: 149:439807  
 TITLE: Iliac Venous Stenting. Antithrombic efficacy of PD0348292, an oral direct factor Xa inhibitor, compared with antiplatelet agents in pigs

AUTHOR(S): McBane, Robert D., II; Leadley, Robert J., Jr.; Baxi, Sangita M.; Karnicki, Krzysztof; Wysokinski, Waldemar  
 CORPORATE SOURCE: Section of Hematology Research, Mayo Clinic, Rochester, MN, USA

SOURCE: Arteriosclerosis, Thrombosis, and Vascular Biology (2008), 28(3), 413-418  
 CODEN: ATVBFA; ISSN: 1079-5642

PUBLISHER: Lippincott Williams & Wilkins  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The clin. use of venous stents is increasing dramatically. Although antiplatelet agents are required for arterial stent patency, optimal thrombo-prophylaxis after venous stenting remains undefined. To address this issue, PD0348292, a direct Factor Xa inhibitor, was compared with antiplatelet therapy in a porcine venous stent model. Four hours before stent deployment, swine (n = 5 to 6 per group) received oral PD0348292 at 0.4, 0.9, 4.3 mg/kg, or 0.4 mg/kg plus aspirin (325 mg). Aspirin, clopidogrel (75 mg), aspirin plus clopidogrel, or vehicle (n=10) were

administered daily for 2 days before the procedure. Two hours after stent placement, thrombi were quantified by autologous  $^{111}\text{In}$ -platelet content and wts. Thrombus weight and platelet deposition were significantly reduced by PD0348292 at 0.4 ( $49 \pm 79$  mg and  $110 \pm 145 + 106/\text{cm}^2$ ), 0.9 ( $5 \pm 6$  mg and  $107 \pm 128 + 106/\text{cm}^2$ ), 4.3 mg/kg ( $0 \pm 0$  mg and  $87 \pm 125 + 106/\text{cm}^2$ ), and PD348292 plus aspirin ( $20 \pm 40$  mg and  $157 \pm 70 + 106/\text{cm}^2$ ) compared with vehicle ( $402 \pm 226$  mg;  $584 \pm 454 + 106/\text{cm}^2$ ). Despite prolonging bleeding times and inhibiting platelet aggregation, neither aspirin ( $567 \pm 683$  mg and  $533 \pm 622 + 106/\text{cm}^2$ ), clopidogrel ( $404 \pm 349$  mg and  $178 \pm 101 + 106/\text{cm}^2$ ), nor aspirin plus clopidogrel ( $247 \pm 261$  mg and  $231 \pm 266 + 106/\text{cm}^2$ ) significantly decreased stent thrombosis. PD0348292 completely inhibited thrombosis after venous stenting. Platelet accretion in these venous thrombi appear to involve pathways distinct from arachidonate metabolism or ADP P2Y12 receptor activation.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1246863 HCPLUS  
 DOCUMENT NUMBER: 149:378433  
 TITLE: Process for the synthesis of factor Xa inhibitors  
 AUTHOR(S): Anon.  
 CORPORATE SOURCE: USA  
 SOURCE: IP.com Journal (2007), 7(10A), 3-4 (No. IPCOM000158184D), 18 Sep 2007  
 CODEN: IJPOBX; ISSN: 1533-0001  
 PUBLISHER: IP.com, Inc.  
 DOCUMENT TYPE: Journal; Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IP 158184D	-----	20070918	IP 2007-158184D	20070918
PRIORITY APPLN. INFO.:			IP 2007-158184D	20070918

OTHER SOURCE(S): CASREACT 149:378433

AB The final synthesis step of a process to produce a Factor Xa inhibitor was challenging due to impurity formation. The impurities were caused by slight under- or over-charge of the reactants. Because of these impurities, charging accuracy had to exceed  $\pm 0.1\text{Kg}$  in the plant in order to avoid a tedious/expensive work-up procedure. In order improve the robustness of this reaction a quenching agent, or "safener", was found that allowed excess of one of the reactants, the isocyanate, to be used. It was determined that with isopropanol present as a "safener" in the reaction mixture up to 40% molar excess of the isocyanate could be charged without any formation of the usual impurities, and none of the urethane formed from the safener ended up in the final product. Thus, the addition of isopropanol greatly expanded the range of acceptable charges and completely eliminated the need for rework of the isolated product. By avoiding the reworks, this safener has increased the yield and greatly improved the robustness of this reaction. The use of isopropanol as a safener has been successfully demonstrated on a large scale. This safener methodol. is most likely applicable to a wide variety of similar transformations.

10594024

L8 ANSWER 5 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2007:1004082 HCPLUS  
DOCUMENT NUMBER: 147:377578  
TITLE: The discovery of  
(2R,4R)-n-(4-chlorophenyl)-n-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor  
AUTHOR(S): Kohrt, Jeffrey T.; Bigge, Christopher F.; Bryant, John W.; Casimiro-Garcia, Agustin; Chi, Ligu; Cody, Wayne L.; Dahring, Tawny; Dudley, Danette A.; Filipski, Kevin J.; Haarer, Staci; Heemstra, Ron; Janiczek, Nancy; Narasimhan, Lakshmi; McClanahan, Thomas; Peterson, J. Thomas; Sahasrabudhe, Vaisheli; Schaum, Robert; Van Huis, Chad A.; Welch, Kathleen M.; Zhang, Erli; Leadley, Robert J.; Edmunds, Jeremy J.  
CORPORATE SOURCE: Michigan Laboratories, Pfizer Global Research & Development, Ann Arbor, MI, 48105, USA  
SOURCE: Chemical Biology & Drug Design (2007), 70(2), 100-112  
CODEN: CBDDAL; ISSN: 1747-0277  
PUBLISHER: Blackwell Publishing Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI



I


AB Herein, we report the discovery of novel, proline-based factor Xa inhibitors containing a neutral P1 chlorophenyl pharmacophore. Through the addnl. incorporation of 1-(4-amino-3-fluoro-phenyl)-1H-pyridin-2-one 22, as a P4 pharmacophore, we discovered compound 7 (PD 0348292, I). This compound is a selective, orally bioavailable, efficacious FXa inhibitor that is currently in phase II clin. trials for the treatment and prevention of thrombotic disorders.

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS

10594024

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2007:809018 HCAPLUS  
DOCUMENT NUMBER: 147:291356  
TITLE: Structure-based drug design of pyrrolidine-1,  
2-dicarboxamides as a novel series of orally  
bioavailable factor Xa inhibitors  
AUTHOR(S): Van Huis, Chad A.; Bigge, Christopher F.;  
Casimiro-Garcia, Agustin; Cody, Wayne L.; Dudley,  
Danette A.; Filipski, Kevin J.; Heemstra, Ronald J.;  
Kohrt, Jeffrey T.; Narasimhan, Lakshmi S.; Schaum,  
Robert P.; Zhang, Erli; Bryant, John W.; Haarer,  
Staci; Janiczek, Nancy; Leadley, Robert J., Jr.;  
McClanahan, Thomas; Peterson, J. Thomas; Welch,  
Kathleen M.; Edmunds, Jeremy J.  
CORPORATE SOURCE: Michigan Laboratories, Pfizer Global Research &  
Development, Ann Arbor, MI, 48105, USA  
SOURCE: Chemical Biology & Drug Design (2007), 69(6), 444-450  
CODEN: CBDDAL; ISSN: 1747-0277  
PUBLISHER: Blackwell Publishing Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI



I

AB A novel series of pyrrolidine-1,2-dicarboxamides was discovered as factor Xa inhibitors using structure-based drug design. This series consisted of a neutral 4-chlorophenylurea P1, a biphenylsulfonamide P4 and a D-proline scaffold (I, IC<sub>50</sub> = 18 nM). Optimization of the initial hit resulted in an orally bioavailable, subnanomolar inhibitor of factor Xa (13, IC<sub>50</sub> = 0.38 nM), which was shown to be efficacious in a canine electrolytic model of thrombosis with minimal bleeding.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:1006402 HCPLUS  
 DOCUMENT NUMBER: 145:377210  
 TITLE: Preparation of polymorphic crystalline forms of N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-(2R,4R)-1,2-pyrrolidinedicarboxamide factor Xa inhibitor  
 INVENTOR(S): Samas, Brian Matthew; Vrieze, Derek Clinton  
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA  
 SOURCE: PCT Int. Appl., 31pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006100565	A1	20060928	WO 2006-IB633	20060313
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006226043	A1	20060928	AU 2006-226043	20060313
CA 2602550	A1	20060928	CA 2006-2602550	20060313
EP 1891044	A1	20080227	EP 2006-727345	20060313
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2006265254	A	20061005	JP 2006-81926	20060324
IN 2007DN06355	A	20070831	IN 2007-DN6355	20070816
MX 200710602	A	20080304	MX 2007-10602	20070830
KR 2007107156	A	20071106	KR 2007-721901	20070921
CN 101146792	A	20080319	CN 2006-80009365	20070921
US 20080194643	A1	20080814	US 2007-909368	20070921
PRIORITY APPLN. INFO.:			US 2005-664870P	P 20050324
			WO 2006-IB633	W 20060313

OTHER SOURCE(S): CASREACT 145:377210

AB Polymorphic crystalline forms of N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-(2R,4R)-1,2-pyrrolidinedicarboxamide factor Xa inhibitor are prepared and characterized by their powder X-ray diffraction, solid-state NMR, etc., and pharmaceutical dosage forms containing it are claimed.


REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:316811 HCPLUS

DOCUMENT NUMBER: 144:370085  
 TITLE: Preparation of 1,2-pyrrolidinedicarboxamides as coagulation factor Xa inhibitors  
 INVENTOR(S): Cezanne, Bertram; Dorsch, Dieter; Mederski, Werner;  
 Tsaklakidis, Christos; Gleitz, Johannes  
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 103 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006034769	A1	20060406	WO 2005-EP9418	20050901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004047254	A1	20060413	DE 2004-102004047254	20040929
AU 2005289164	A1	20060406	AU 2005-289164	20050901
CA 2581732	A1	20060406	CA 2005-2581732	20050901
EP 1797071	A1	20070620	EP 2005-790356	20050901
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101031561	A	20070905	CN 2005-80032789	20050901
JP 2008514655	T	20080508	JP 2007-533891	20050901
BR 2005015577	A	20080729	BR 2005-15577	20050901
MX 200703470	A	20070510	MX 2007-3470	20070323
KR 2007057878	A	20070607	KR 2007-707053	20070328
US 20080081814	A1	20080403	US 2007-576207	20070328
IN 2007KN01474	A	20070720	IN 2007-KN1474	20070425
PRIORITY APPLN. INFO.:			DE 2004-102004047254A	20040929
			WO 2005-EP9418	W 20050901

OTHER SOURCE(S): MARPAT 144:370085  
 GI



AB Title compds. I [R1, R2 = H, =O, halo, etc.; R3 = H, CH<sub>2</sub>CH(OH)CH<sub>2</sub>OH, CH<sub>2</sub>CH(OH)CH<sub>2</sub>NH<sub>2</sub>, etc.; W = N, CR<sub>3</sub> with provisos, etc.; E = together with W form a 3 to 7-membered hetero or carbocyclic ring with provisos; D = bond, double bond, etc.; G = [C(R<sub>4</sub>)<sub>2</sub>]n, [C(R<sub>4</sub>)<sub>2</sub>]nNR<sub>3</sub>, [C(R<sub>4</sub>)<sub>2</sub>]nO, etc.; R<sub>4</sub> = H, A; A = alkyl with provisos; X = [C(R<sub>4</sub>)<sub>2</sub>]nCONR<sub>3</sub>[C(R<sub>4</sub>)<sub>2</sub>]n, etc.; n = 0-2; Y = alkylene, cycloalkylene, etc.; T = bond, double bond, heterocycle with provisos, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, O-acylation of hydroxypyrrolidine II [Z = H] afforded pyrrolidinedicarboxamide II [Z = CO<sub>2</sub>Et]. In coagulation factor Xa inhibition assays, pyrrolidinedicarboxamide II [Z = CO<sub>2</sub>Et] exhibited an IC<sub>50</sub> value of 2.0x10<sup>-9</sup> M.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:273940 HCPLUS

DOCUMENT NUMBER: 144:331461

TITLE: Drugs containing carbonyl compounds and their use for the prophylaxis and/or therapy of thromboembolic illnesses

INVENTOR(S): Cezanne, Bertram; Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: Ger. Offen., 77 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004045796	A1	20060323	DE 2004-102004045796	20040922
AU 2005287637	A1	20060330	AU 2005-287637	20050824
CA 2581172	A1	20060330	CA 2005-2581172	20050824
WO 2006032342	A2	20060330	WO 2005-EP9124	20050824
WO 2006032342	A3	20070111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1791597	A2	20070606	EP 2005-774750	20050824
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101102818	A	20080109	CN 2005-80031723	20050824
JP 2008513387	T	20080501	JP 2007-531628	20050824
BR 2005015592	A	20080729	BR 2005-15592	20050824

MX 200703175	A	20070518	MX 2007-3175	20070316
KR 2007054210	A	20070528	KR 2007-706440	20070321
US 20080003214	A1	20080103	US 2007-575711	20070321
IN 2007KN01362	A	20070720	IN 2007-KN1362	20070418
PRIORITY APPLN. INFO.:			DE 2004-102004045796A	20040922
			WO 2005-EP9124	W 20050824

OTHER SOURCE(S): MARPAT 144:331461  
GI




AB Use of heterocyclic carbonyl compds. I [R1, R2 = H, :O:, halogen, A, C.tplbond.CH, OR3,N(R3)2, NO2, CN, N3, CO2R3, CON(R3)2, [C(R4)2]n-Ar, [C(R4)2]n-heterocyclyl, [C(R4)2]n-cycloalkyl, OC(:O)R3, OC(:O)N(R3)2, NR3COA, NR3SO2A; R1R2 = bi- or spirocyclic 3- to 7-membered carbocycle or heterocycle (containing 0 - 3 N, O, or S); R3 = H, A, CH2C.tplbond.CH, CH2CH(OH)CH2OH, CH2CH(OH)CH2NH2, CH2CH(OH)CH2-heterocycle, [C(R4)2]n-Ar, [C(R4)2]n-heterocyclyl, [C(R4)2]n-cycloalkyl, [C(R4)2]n-CO2A, [C(R4)2]nN(R4)2; R4 = H, A; EW = 3- to 7-membered carbocycle or heterocycle (containing 0 - 3 N, O, or S); W = N, CR3, sp2-C; D = mono- or binuclear, (un)substituted aromatic carbocycle or heterocycle (containing 0 - 3 N, O, or S); G = [C(R4)2]n, [C(R4)2]n-NR3, [C(R4)2]nO, [C(R4)2]nS, [CR4:CR4]n; X = [C(R4)2]nCONR3[C(R4)2]n, [C(R4)2]nNR3CO[C(R4)2]n, [C(R4)2]nNR3[C(R4)2]n, [C(R4)2]nO[C(R4)2]n, [C(R4)2]nC(:O)[C(R4)2]n, [C(R4)2]nCO2[C(R4)2]n; Y = alkylene, cycloalkylene, heterodiyl, aryldiyl; T = mono- or binuclear, (un)substituted aromatic carbocycle or heterocycle (containing 0 - 3 N, O, or S); A = (un)branched C1-10-alkyl (optionally containing, O, S or CH:CH in the chain and replacing 1 - 7 H with F); n = 0 - 2; o = 1 - 3], their derivs., solvates, salts and stereoisomers, for the prophylaxis and/or therapy of thromboembolic illnesses. Thus, proline derivative II was prepared from N-Boc-D-proline via amidation with 4-(4-aminophenyl)morpholin-3-one in DMF containing 1-hydroxybenzotriazole hydrate, N-[3-(dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride and N-methylmorpholine, N-deprotection with aqueous HCl in dioxane and carbamylation with 4-ClC6H4NCO in CH2Cl2 containing Et3N. The receptor

binding activity of II was determined [IC<sub>50</sub> = 1.8 × 10<sup>-8</sup> M vs. FXa; IC<sub>50</sub> = 2.3 × 10<sup>-8</sup> M vs. TF/FVIIa].

L8 ANSWER 10 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:1075769 HCPLUS  
 DOCUMENT NUMBER: 143:347450  
 TITLE: Synthesis of prolinyl derivatives for use in the treatment of thromboembolic diseases or tumors  
 INVENTOR(S): Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram; Gleitz, Johannes  
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 51 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092849	A1	20051006	WO 2005-EP2306	20050304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004014945	A1	20051013	DE 2004-102004014945	20040326
AU 2005225489	A1	20051006	AU 2005-225489	20050304
CA 2561057	A1	20051006	CA 2005-2561057	20050304
EP 1735279	A1	20061227	EP 2005-715737	20050304
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
CN 1938269	A	20070328	CN 2005-80009735	20050304
BR 2005009174	A	20070918	BR 2005-9174	20050304
JP 2007530469	T	20071101	JP 2007-504284	20050304
IN 2006KN02397	A	20070525	IN 2006-KN2397	20060824
MX 2006PA10771	A	20061215	MX 2006-PA10771	20060920
KR 2007010131	A	20070122	KR 2006-719772	20060925
US 20070135507	A1	20070614	US 2006-594024	20060925
PRIORITY APPLN. INFO.:			DE 2004-102004014945A	20040326
			WO 2005-EP2306	W 20050304

OTHER SOURCE(S): MARPAT 143:347450  
 GI



AB The invention relates to title compds., e.g. (I), which are inhibitors of coagulation factors Xa and VIIa and can be used for the prophylaxis and/or treatment of thromboembolic diseases and for the treatment of tumors (no data). Thus, (II) was prepared by condensation of (2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-Bu ester with 4'-amino-N,N-dimethyl-[1,1'-biphenyl]-2-methanamine, followed by condensation with 4-nitrophenyl chloroformate and 4-chloroaniline, to give II (no yield). Sixteen title compds. are claimed, and formulations for administration (e.g., injections, suppositories, etc.) are given.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:564637 HCPLUS

DOCUMENT NUMBER: 143:97636

TITLE: Synthesis of prolinylarylacetamides as coagulation factor Xa inhibitors for use in the prevention or treatment of thromboembolic diseases or tumors

INVENTOR(S): Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058817	A1	20050630	WO 2004-EP13509	20041126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,  
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG  
 DE 10358814 A1 20050721 DE 2003-10358814 20031216  
 AU 2004299197 A1 20050630 AU 2004-299197 20041126  
 CA 2549589 A1 20050630 CA 2004-2549589 20041126  
 EP 1697318 A1 20060906 EP 2004-820404 20041126  
 EP 1697318 B1 20080827  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS  
 CN 1894210 A 20070110 CN 2004-80037698 20041126  
 BR 2004017630 A 20070327 BR 2004-17630 20041126  
 JP 2007513988 T 20070531 JP 2006-544256 20041126  
 AT 406350 T 20080915 AT 2004-820404 20041126  
 IN 2006KN01579 A 20070504 IN 2006-KN1579 20060608  
 MX 2006PA06740 A 20060818 MX 2006-PA6740 20060614  
 US 20070185189 A1 20070809 US 2006-583094 20060615  
 PRIORITY APPLN. INFO.: DE 2003-10358814 A 20031216  
 WO 2004-EP13509 W 20041126

OTHER SOURCE(S): MARPAT 143:97636  
 GI



AB Title compds., e.g. (I), are claimed as inhibitors of coagulation factor Xa and are claimed for use for the prophylaxis and/or therapy of thromboembolic diseases and in the treatment of tumors, as well as kits containing the compds. of interest. Thus, the title compds. were prepared, e.g., by condensation of (2R,4R)-1-(4-chlorophenylcarbamoyl)-4-hydroxyproline and N-(4-aminophenyl)2-dimethylamino-N-Me acetamide in DMF using N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride as condensing agent. In pharmacol. testing, I had receptor affinity IC<sub>50</sub> values of 17.0 nM and 25.0 M using FXa and TF/FVIIa receptors, resp. (no details given). Various formulations for administering the title compds. therapeutically are given.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:857591 HCPLUS  
 DOCUMENT NUMBER: 141:314626  
 TITLE: Method for the production of

pyrrolidine-1,2-dicarboxylic  
acid-1-(phenyl(-amide))-2-(phenyl(-amide)) derivatives  
and 1-(phenylcarbamoyl)-pyrrolidine-2-carboxylic acid  
derivatives as intermediate products

INVENTOR(S): Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: PCT Int. Appl., 42 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: German

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087695	A1	20041014	WO 2004-EP2405	20040309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10315377	A1	20041014	DE 2003-10315377	20030403
DE 10327428	A1	20050105	DE 2003-10327428	20030618
DE 10329295	A1	20050203	DE 2003-10329295	20030630
DE 10329457	A1	20050120	DE 2003-10329457	20030701
DE 10334174	A1	20050217	DE 2003-10334174	20030726
AU 2004226280	A1	20041014	AU 2004-226280	20040309
CA 2520893	A1	20041014	CA 2004-2520893	20040309
EP 1608646	A1	20051228	EP 2004-718646	20040309
EP 1608646	B1	20070711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008888	A	20060411	BR 2004-8888	20040309
JP 2006522037	T	20060928	JP 2006-504602	20040309
EP 1760081	A1	20070307	EP 2006-22891	20040309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV				
US 20060211692	A1	20060921	US 2005-551670	20050930
IN 2005KN02182	A	20060929	IN 2005-KN2182	20051103
PRIORITY APPLN. INFO.:			DE 2003-10315377	A 20030403
			DE 2003-10327428	A 20030618
			DE 2003-10329295	A 20030630
			DE 2003-10329457	A 20030701
			DE 2003-10334174	A 20030726
			EP 2004-718646	A3 20040309
			WO 2004-EP2405	W 20040309

OTHER SOURCE(S): CASREACT 141:314626; MARPAT 141:314626  
GI



AB The invention relates to a method for the production of title compds., e.g. (I), and intermediate products, e.g. (II) for the production of I. Thus, cis-hydroxy-D-proline was reacted with 4-chlorophenylisocyanate in NaHCO<sub>3</sub> at 80° for 5 h. to give after workup 81.8% (R,R)-II. II was then reacted with 4-(3-oxo-4-morpholinyl)aniline in THF with 2-ethoxy-1(2H)-quinolinecarboxylic acid Et ester (EEDQ) as coupling agent at room temperature for 20 h to give, after workup, 69% (R,R)-I.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:857551 HCAPLUS

DOCUMENT NUMBER: 141:350179

TITLE: Preparation of azolidinedicarboxamides and related compounds as Factor Xa and Factor VIIa inhibitors

INVENTOR(S): Tsaklakidis, Christos; Dorsch, Dieter; Mederski, Werner; Cezanne, Bertram; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: PCT Int. Appl., 162 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 5


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087646	A2	20041014	WO 2004-EP2350	20040308
WO 2004087646	A3	20050106		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,			

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
 TD, TG

DE 10315377	A1	20041014	DE 2003-10315377	20030403
DE 10329295	A1	20050203	DE 2003-10329295	20030630
AU 2004226278	A1	20041014	AU 2004-226278	20040308
CA 2521069	A1	20041014	CA 2004-2521069	20040308
BR 2004008420	A	20060321	BR 2004-8420	20040308
JP 2006522033	T	20060928	JP 2006-504581	20040308
EP 1720844	A2	20061115	EP 2004-718299	20040308
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV				
RU 2337099	C2	20081027	RU 2005-133870	20040308
IN 2005KN01684	A	20070727	IN 2005-KN1684	20050823
US 20060183739	A1	20060817	US 2005-551557	20051003
PRIORITY APPLN. INFO.:				
			DE 2003-10315377	A 20030403
			DE 2003-10329295	A 20030630
			US 2003-483897P	P 20030702
			WO 2004-EP2350	W 20040308

OTHER SOURCE(S): MARPAT 141:350179  
 GI



AB R1R2(TYX)EWC0GD [R1, R2 = H, O, halo, A, ethynyl, OR3, N(R3)2, NO2, cyano, N3, CO2R3, CON(R3)2, etc.; R3 = H, A, HC.tplbond.CCH2, MeC.tplbond.CCH2, CH2CH(OH)CH2OH, etc.; R4 = H, A; W = N, C, CR3; E = atoms to form a 3-7 membered (heterocyclic) ring optionally containing a double bond; D = mono- or dinuclear (substituted) (hetero)aryl; G = [C(R4)2]n, [C(R4)2]nNR3, [C(R4)2]nO, [C(R4)2]nS, etc.; n = 0-2; X = [C(R4)2]nCO[C(R4)2]n, [C(R4)2]n, NR3[C(R4)2]n, [C(R4)2]nNR3CO[C(R4)2]n, etc.; Y = alkylene, cycloalkylene, heterocyclylene, arenediyl; T = substituted mono- or dinuclear carbocyclyl, heterocyclyl; A = (fluoro-substituted) alkyl optionally interrupted by O, S, CH:CH], were prepared. Thus, title compound (I) [preparation from 4-(4-aminophenyl)morpholin-3-one, Boc-D-proline, and 4-chlorophenyl isocyanate given] bound to Factor Xa receptors with IC50 = 1.8 + 10-8 M.

L8 ANSWER 14 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:841766 HCPLUS

DOCUMENT NUMBER: 141:332202

TITLE: Preparation of azolidinecarboxamides as antithrombotics and anticancer drugs.

INVENTOR(S): Tsaklakidis, Christos; Dorsch, Dieter; Mederski, Werner; Cezanne, Bertram; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany  
 SOURCE: Ger. Offen., 47 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10315377	A1	20041014	DE 2003-10315377	20030403
AU 2004226278	A1	20041014	AU 2004-226278	20040308
CA 2521069	A1	20041014	CA 2004-2521069	20040308
WO 2004087646	A2	20041014	WO 2004-EP2350	20040308
WO 2004087646	A3	20050106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2004008420	A	20060321	BR 2004-8420	20040308
CN 1771237	A	20060510	CN 2004-80009354	20040308
JP 2006522033	T	20060928	JP 2006-504581	20040308
EP 1720844	A2	20061115	EP 2004-718299	20040308
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV				
RU 2337099	C2	20081027	RU 2005-133870	20040308
AU 2004226280	A1	20041014	AU 2004-226280	20040309
AU 2004226281	A1	20041014	AU 2004-226281	20040309
CA 2520893	A1	20041014	CA 2004-2520893	20040309
CA 2520894	A1	20041014	CA 2004-2520894	20040309
WO 2004087695	A1	20041014	WO 2004-EP2405	20040309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004087696	A1	20041014	WO 2004-EP2407	20040309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
 TD, TG  
 EP 1608645 A1 20051228 EP 2004-718641 20040309  
 EP 1608645 B1 20070502  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK  
 EP 1608646 A1 20051228 EP 2004-718646 20040309  
 EP 1608646 B1 20070711  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK  
 BR 2004008444 A 20060404 BR 2004-8444 20040309  
 BR 2004008888 A 20060411 BR 2004-8888 20040309  
 CN 1771248 A 20060510 CN 2004-80009374 20040309  
 CN 1771249 A 20060510 CN 2004-80009463 20040309  
 JP 2006522037 T 20060928 JP 2006-504602 20040309  
 JP 2006522038 T 20060928 JP 2006-504604 20040309  
 AT 361296 T 20070515 AT 2004-718641 20040309  
 AT 366732 T 20070815 AT 2004-718646 20040309  
 ES 2285444 T3 20071116 ES 2004-718641 20040309  
 ES 2287708 T3 20071216 ES 2004-718646 20040309  
 IN 2005KN01684 A 20070727 IN 2005-KN1684 20050823  
 US 20060211692 A1 20060921 US 2005-551670 20050930  
 US 20060183739 A1 20060817 US 2005-551557 20051003  
 US 20060183742 A1 20060817 US 2005-551559 20051003  
 IN 2005KN02182 A 20060929 IN 2005-KN2182 20051103  
 IN 2005KN02183 A 20070323 IN 2005-KN2183 20051103  
 PRIORITY APPLN. INFO.: DE 2003-10315377 A 20030403  
DE 2003-10327428 A 20030618  
DE 2003-10329295 A 20030630  
DE 2003-10329457 A 20030701  
US 2003-483897P P 20030702  
DE 2003-10334174 A 20030726  
DE 2003-10336570 A 20030808  
WO 2004-EP2350 W 20040308  
WO 2004-EP2405 W 20040309  
WO 2004-EP2407 W 20040309

OTHER SOURCE(S):

MARPAT 141:332202

GI



AB R1R2(TYX)EWCOGD [R1, R2 = H, O, halo, A, ethynyl, OR3, NO2, cyano, N3, CO2R3, CON(R3)2, NR3COA, NR3SO2A, etc.; R1R2 = toms to form a bicyclic or spirocyclic (heterocyclic) ring; R3 = H, A, etc.; R4 = H, A; W = N, CR3, C; E = atoms to form a 3-7 membered (double bond containing) (heterocyclic) ring with W; G = [C(R4)2]n, [C(R4)2]nNR3, [C(R4)2]nO, [C(R4)2]nS; X =

[C(R<sub>4</sub>)<sub>2</sub>]nCONR<sub>3</sub>[C(R<sub>4</sub>)<sub>2</sub>]n, [C(R<sub>4</sub>)<sub>2</sub>]nON[C(R<sub>4</sub>)<sub>2</sub>]n, etc.; Y = alkylene, cycloalkylene, (substituted) heterocyclylene, arylene; T = mono- or bicyclic substituted (unsatd.) (hetero)cyclyl; A = (fluoro-substituted) alkylene optionally interrupted by O, S, CH:CH; n = 0-2], were prepared Thus, title compound (I) (prepared from 4-(4-aminophenyl)morpholin-3-one, Boc-D-proline, and 4-chlorophenyl isocyanate), bound to Factor Xa receptors with IC<sub>50</sub> = 1.8 + 10<sup>-8</sup> M.

L8 ANSWER 15 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:799558 HCPLUS  
 DOCUMENT NUMBER: 141:296012  
 TITLE: Preparation of factor Xa- and thrombin-inhibiting substituted benzamidines and sulfonylbenzamidines as potential anticoagulants  
 INVENTOR(S): Pinto, Donald J.; Qiao, Jennifer X.; Gangor, Timur; Lam, Patrick Y. S.; Li, Yun-long  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 279 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083174	A2	20040930	WO 2004-US8033	20040317
WO 2004083174	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040209863	A1	20041021	US 2004-801518	20040316
US 7122557	B2	20061017		
EP 1603562	A2	20051214	EP 2004-757516	20040317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRIORITY APPLN. INFO.:			US 2003-455709P	P 20030318
			US 2004-801518	A 20040316
			WO 2004-US8033	W 20040317

OTHER SOURCE(S): MARPAT 141:296012  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Compds. P4-M-M4 (I) [M = (un)substituted 3-10 membered carbocyclic or a 4-10 membered heterocyclic ring containing 1-3 O, N, or S atoms, alone or

fused to an (un)substituted 5-7 membered carbocycle or heterocycle; P4 = Z-A-B; M4 = G-G1; A = (un)substituted 3-10 membered carbocyclic or 5-12 membered heterocyclic ring; B = (un)substituted amidino, guanidino, iminomethyl; G = five or six-membered carbocycle or heterocycle fused to a benzene, pyridine, pyrimidine, pyrazine, or pyridazine ring; G1 = bond, (un)substituted alkyl, alkenyl, alkynyl; Z = (un)substituted alkylene], such as tetrahydropyrazolo[3,4-c]pyridinone II or (pyridinylaminocarbonylphenylaminocarbonyl)benzamidine III are prepared as inhibitors of Factor Xa and thrombin for use as anticoagulants. Deprotonation of 2-amino-4-chloropyridine and addition to 5-chloroisatoic anhydride yields N-(5-chloro-2-pyridinyl) 2-amino-5-chlorobenzamide (IV). Acid-mediated addition of dimethylamine to the nitrile of Me 4-cyanobenzoate, mesylation of the amidine nitrogen, and base-mediated hydrolysis of the ester yields 4-(N,N-dimethyl-N'-methylsulfonylamidino)benzoic acid (V). Coupling of IV and V mediated by BOP yields III. Some compds. of the invention inhibit human factor Xa with Ki values of  $\leq 10 \mu\text{M}$ ; in addition, some of the invention compds. inhibit thrombin in vitro. (no data).

L8 ANSWER 16 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:434528 HCPLUS

DOCUMENT NUMBER: 139:6763

TITLE: Preparation of pyrrolidinedicarboxamides and related compounds as inhibitors of factor Xa useful for thrombotic disorders

INVENTOR(S): Bigge, Christopher Franklin; Dudley, Danette Andrea; Edmunds, Jeremy John; Van Huis, Chad Alan; Casimiro-Garcia, Agustin; Filipski, Kevin James; Kohrt, Jeffrey Thomas

PATENT ASSIGNEE(S): Warner-Lambert Company L.L.C., USA

SOURCE: PCT Int. Appl., 389 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045912	A1	20030605	WO 2002-IB4757	20021114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030162787	A1	20030828	US 2002-278643	20021023
US 7030141	B2	20060418		
CA 2468715	A1	20030605	CA 2002-2468715	20021114
AU 2002365313	A1	20030610	AU 2002-365313	20021114
AU 2002365313	B2	20080306		
BR 2002014519	A	20041013	BR 2002-14519	20021114
EP 1465864	A1	20041013	EP 2002-803885	20021114
EP 1465864	B1	20060315		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1582274	A	20050216	CN 2002-823837	20021114
HU 2004002529	A2	20050329	HU 2004-2529	20021114
JP 2005515985	T	20050602	JP 2003-547364	20021114
AT 320414	T	20060415	AT 2002-803885	20021114
EP 1671949	A2	20060621	EP 2006-110738	20021114
EP 1671949	A3	20060719		
EP 1671949	B1	20080723		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PT 1465864	T	20060630	PT 2002-803885	20021114
ES 2259113	T3	20060916	ES 2002-803885	20021114
NZ 532384	A	20061027	NZ 2002-532384	20021114
AP 1744	A	20070630	AP 2004-3035	20021114
AT 402148	T	20080815	AT 2006-110738	20021114
MX 2004PA03606	A	20040727	MX 2004-PA3606	20040416
ZA 2004004085	A	20050905	ZA 2004-4085	20040525
NO 2004002270	A	20040601	NO 2004-2270	20040601
US 20050267118	A1	20051201	US 2004-17598	20041220
US 7407972	B2	20080805		
US 20050250815	A1	20051110	US 2005-108582	20050418
US 7407974	B2	20080805		
US 20060264626	A1	20061123	US 2006-461859	20060802
PRIORITY APPLN. INFO.:			US 2001-334168P	P 20011129
			US 2002-384895P	P 20020531
			US 2002-278643	A3 20021023
			EP 2002-803885	A3 20021114
			WO 2002-IB33416	A 20021114
			WO 2002-IB4757	W 20021114
			US 2004-17598	A3 20041220

OTHER SOURCE(S): MARPAT 139:6763  
GI



AB The present invention provides pyrrolidinedicarboxamides and related compds. (shown as I; variables defined below; e.g. (R)-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide]) and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compns. comprising  $\geq 1$  compds. I, processes for preparing I, and intermediates useful for preparing I. IC<sub>50</sub> values for inhibition of factor Xa are tabulated for >170 examples of I. About 180 example preps. of I are included. For example, (R)-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] was prepared in 4 steps starting from Fmoc-D-Pro, SOCl<sub>2</sub>, and 4-bromo-2-fluoroaniline and involving intermediates (R)-2-[(4-bromo-2-fluorophenyl)carbamoyl]pyrrolidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester, (R)-pyrrolidine-2-carboxylic acid (2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide, and

(R)-pyrrolidine-1,2-dicarboxylic acid  
 2-[ (2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide]  
 1-[ (4-chlorophenyl)amide] with yields of 99, 70, 66 and 76%, resp. Four pharmaceutical formulations are described. For I: A is (un)substituted aryl or (un)substituted monocyclic heteroaryl; B is -NHC(O)(C1-C6)alkyl, -NHC(O)(C3-C7)cycloalkyl, -NHC(O)O(C1-C6 alkyl), -C(O)R1, (C3-C7)cycloalkyl, (C3-C7)heterocyclo, (C4-C7)cycloalkenyl, unsatd. (C4-C7)heterocyclo, aryl, or heteroaryl, any of which may be (un)substituted by halo, (C1-C6)alkyl, or halo(C1-C6)alkyl, O(C1-C6), -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido. C is Ph or heteroaryl, wherein Ph or heteroaryl is (un)substituted with  $\geq 1$  substituents = aryl, heteroaryl, halogen, hydroxy, -CO<sub>2</sub>R<sub>2</sub>, -COR<sub>2</sub>, -CONR<sub>2</sub>R'<sub>2</sub>, alkoxy, alkyl, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido; G is H, halo, (C1-C6)alkyl, halo(C1-C6)alkyl, hydroxy(C1-C6)alkyl, -CH<sub>2</sub>O(C1-C6)alkyl, -CH<sub>2</sub>CO<sub>2</sub>(C1-C6)alkyl, -CH<sub>2</sub>NR<sub>2</sub>R'<sub>2</sub>, or -CH<sub>2</sub>C(O)NH(C1-C6)alkyl. W<sub>1</sub> is a saturated or unsatd., (un)substituted hydrocarbon chain or hydrocarbon-heteroatom chain having 2-6 atoms, wherein W<sub>1</sub> connects the N atom at position 1 to the C atom at position 2 to form a four to eight membered ring; R<sub>1</sub> is (C1-C6)alkoxy, (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, (C4-C7) cycloalkenyl, (C4-C7)heterocycloalkenyl, aryl, monocyclic heteroaryl, or -NR<sub>3</sub>R<sub>4</sub>; R<sub>2</sub> and R<sub>2'</sub> are each independently H or (C1-C6)alkyl; and R<sub>3</sub> and R<sub>4</sub> are each independently H, (C1-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO<sub>2</sub>alkyl, or joined together to form a saturated or unsatd. 3 to 7 membered ring.


REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 17 HCPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1998:352811 HCPLUS  
 DOCUMENT NUMBER: 129:40984  
 ORIGINAL REFERENCE NO.: 129:8615a,8618a  
 TITLE: Preparation of acylamino-substituted acylanilide derivatives as antiandrogenic agents  
 INVENTOR(S): Taniguchi, Nobuaki; Okada, Minoru; Kaku, Hidetaka; Shimada, Itsuro; Nozawa, Eisuke; Koutoku, Hiroshi; et al.  
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 58 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9822432	A1	19980528	WO 1997-JP4174	19971117
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9749664	A	19980610	AU 1997-49664	19971117
PRIORITY APPLN. INFO.:			JP 1996-306192	A 19961118

OTHER SOURCE(S):  
GI

MARPAT 129:40984



AB The title compds. [I; R1, R2 = halo, cyano, haloalkyl, NO<sub>2</sub>, etc.; R3 = H, lower alkyl; R4-R7 = H, (un)substituted lower alkyl, aralkyl, etc.; R8 = H, OH, lower alkoxy or alkyl, etc.; n = 0, 1; A1, A2 = lower alkylene; Z = acyl; X1 = O, S] are prepared I have an antiandrogenic activity and are useful as a prophylactic or therapeutic agent for prostatic cancer, prostatic hypertrophy, defeminization, hypertrichosis, bald head, acne, seborrhea and the like in which androgen is involved as an exacerbating factor. Thus, p-FC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>NHC<sub>2</sub>H<sub>5</sub>CO<sub>2</sub>H was treated with (COCl)<sub>2</sub> and then reacted with 4-amino-2-trifluoromethylbenzonitrile to give I (R1 = CF<sub>3</sub>, R2 = cyano, R3 = R5 = H, n = 0, Z = p-FC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>, X1 = O), which showed IC<sub>50</sub> of 0.56 nM antagonist activity when tested with androgen receptor.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
	ENTRY	SESSION	
FULL ESTIMATED COST	119.83	478.14	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL	
	ENTRY	SESSION	
CA SUBSCRIBER PRICE	-18.40	-18.40	

STN INTERNATIONAL LOGOFF AT 09:20:55 ON 14 NOV 2008